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ABSTRACT
Ordered protein aggregation in the brain is a hallmark of Alzheimer's
disease (AD). The disease-specific amyloid fibrils which form the core of
neuritic plaques are formed by the 4-kilodalton P amyloid protein (AP). This
protein can be induced to form aggregates in vitro which are
indistinguishable from brain-derived fibrils. Consequently, a large amount of
effort has been invested in the development of in vitro model systems to
study the details of the aggregation process and the effects of endogenous
molecules which have been implicated in disease. A simple mechanistic
model has emerged for A1 amyloid formation which involves a nucleation-
dependent polymerization process. To test the basic features of the model, a
series of experiments have been performed using atomic force microscopy
(AFM) to follow the progress of A3 fibril formation in vitro. These studies
have detected a heterogeneous group of oligomeric AP species which are
transiently populated before the onset of fibril formation. Among these
species is an elongated flexible species with a diameter of approximately 4 n m
that we have termed AP amyloid protofibrils. Protofibrils elongate slowly
with time under a variety of in vitro conditions with a rate that is sensitive to
changes in A3 concentration, incubation temperature, and ionic strength, and
ultimately disappear as amyloid fibrils of at least two types are formed. An
expanded model of AP fibril formation is presented, based on these and other
observations, in which AP amyloid fibrils are formed by lateral association
and winding of protofibrils and stabilized by a conformational change. The
presence of protofibrils during the initial stages of fibril formation in vitro
suggests that protofibrils may also form early in AD. If these transient
intermediates are found in the brain, they would provide attractive targets for
AD therapeutics aimed at inhibiting amyloid formation and AD diagnostics
aimed at detecting presymptomatic disease.
Thesis Supervisor: Peter T. Lansbury, Jr.
Title: Associate Professor of Chemistry
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Chapter 1
AP Amyloid Fibril Formation: A Nucleation Dependent Process
Alzheimer's disease (AD) is a late-onset, progressive neurodegenerative
disease which is characterized by ordered protein aggregation in the brain. 1-5
The highly insoluble AD-specific aggregates, known as amyloid fibrils, comprise
primarily variants of the A3 protein (Figure 1.1).3 Circumstantial evidence
suggests that the AB amyloid fibril may initiate neurodegeneration in vivo.1, 3,6-8
Hence, the inhibition of AB aggregation may represent a feasible therapeutic
strategy against AD.9-12 It is, therefore, critical to understand the detailed
molecular mechanism of A3 amyloid formation and to elucidate the role of
endogenous factors which appear to inhibit amyloidogenesis in the normal brain
and/or promote it in the AD brain.
The family of AB variants are derived from the amyloid precursor protein
(APP), a widely-expressed ca. 700-amino acid cell-surface protein of unknown
function.1, 3 All forms of early-onset AD affect the expression and/or processing
of APP. 8 Trisomy of the APP-bearing chromosome (chomosome 21) is
characteristic of Down syndrome; these individuals invariably develop the
neuropathological features of AD in their forties. 13 Mutations in the APP gene
cause early-onset familial AD (FAD) and affect the production of A3 variants
from APP in culture by transfected mammalian cell lines. 3,8 Two variants, Apl-
40 and A31-42, which differ by truncation at the carboxyl terminus (Figure 1.1),
are the predominant plaque proteins. 8 Both are found in the blood and
cerebrospinal fluid (CSF) at nanomolar levels. 14 The combined concentration of
the A3 variants in plasma and CSF does not vary significantly in most AD
patients.14,15 However, the plasma concentration of the minor plasma protein
Af1-42 increases in FAD patients bearing an APP mutation, and also, strikingly,
in FAD patients bearing mutations on chromosomes 1 (presenilin 2) or 14
(presenilin 1).16 In addition, Apl-42 constitutes a larger portion of total A in
amyloid plaques from FAD patients as compared to those from late-onset AD
patients. 17,18 These findings suggest a possible role for A31-42 in AD
pathogenesis, a possibility discussed below.
Apl-40 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
APl-42 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Figure 1.1 Sequences of the two major AD amyloid fibril proteins, Apl-40 and
A01-42.
Native-like AD amyloid fibrils have been produced from synthetic A3
variants (see below). 19,20 It is therefore possible to devise simple in vitro models
of the complex in vivo aggregation process. Such models have been used to
screen compound libraries for inhibitors of aggregation which may have
therapeutic efficacy against AD. 11 In addition, in vitro models will be useful for
elucidating the molecular details of the aggregation processes, for facilitating the
understanding of known genetic risk factors for AD, and, possibly, for
discovering novel potential protein risk factors, which could then be investigated
by targeted genetic screening.5 A prerequisite to elucidation of the pathway is
the understanding of the structural aspects of the aggregation process; the
conformational properties of the starting AB protein and the structure of the
product AD amyloid fibril. 5,2 1,22
Once a simple in vitro model for amyloidogenesis has been developed and
shown to recapitulate what is known about the in vivo process, it can be used to
evaluate the effects of disease-associated biochemical changes characteristic of
AD (increases in Af concentration, Apolipoprotein E (apoE) genotype, etc.--see
below) on the aggregation process. In doing so, it is critical to distinguish
between effects on the structure, solubility, or stability of aggregates and effects
on the rate of aggregate formation. Perturbations of the structural properties of a
protein in its soluble or fibrillar state can be measured (SSNMR, FTIR, CD, gel
filtration, SDS-PAGE, electron microscopy, etc.) but do not necessarily correlate
to effects on the aggregation rate. Conversely, perturbations of the rate of
amyloid formation are not necessarily linked to structural effects. For example,
ApoE3 decreases the rate of Apl-40 amyloid formation in vitro but does not seem
to affect the structure or solubility of the product amyloid fibril 23,24 (this
interpretation has been disputed by other laboratories, 25,26 see below).
The key to understanding the rate of amyloid formation involves the
identification of its slowest, or rate-determining, step in the overall process. This
is the step which may be responsible for protecting normal individuals from
amyloid formation. The disease may result from acceleration of this step and,
therefore, the overall process; perturbation of other steps may have no effect.
For instance, since most protein conformational changes are much faster than
amyloid formation, perturbations of the monomer conformational dynamics are
unlikely to affect the overall rate. The slow step in amyloid formation seems to
be the formation of an ordered oligomeric nucleus (Figure 1.2).27
NUCLEATION-DEPENDENT AD AMYLOID FORMATION
Protein crystallization is a highly ordered process which occurs via a
nucleation-dependent pathway.2 8 Physiological ordered protein aggregation
processes as diverse as viral coat assembly,29 microtubule formation, 30 flagellum
formation,3 1 and sickle-cell hemoglobin fibril formation 32 also occur by a
nucleation-dependent polymerization pathway. These processes are
characterized by (a) a slow nucleation phase, in which the protein undergoes a
series of unfavorable association steps to form an ordered oligomeric nucleus, (b)
a growth phase in which the nucleus rapidly grows to form larger polymers, and
(c) a steady state phase, in which the ordered aggregate and the monomer appear
to be at equilibrium.33,34
Kn Kg
lag time
seeded growth
Figure 1.2 A schematic depicting the simplest nucleation-dependent
mechanism. A series of unfavorable protein-protein association equilibria
(Kn) lead to an unstable nucleus, followed by a series of favorable equilibria
(Kg), culminating in fibril formation. The critical concentration phenomenon
results from the shift from unfavorable (Kn) to favorable (Kg) equilibrila.
The characteristic features of a typical nucleation-dependent
polymerization are as follows: (a) No aggregation occurs at a protein
concentration below the critical concentration, (b) At protein concentrations
which exceed the critical concentration by a small amount, there is a lag time
before polymerization occurs, and (c) During the lag time, addition of a seed
results in immediate polymerization.3 1-34 Each of these characteristics will be
considered in turn, citing specific experiments involving in vitro AP amyloid
formation.
Critical Concentration
In a typical nucleation-dependent polymerization, polymer is not
observed at equilibrium until the monomer concentration exceeds a certain level,
known as the critical concentration (Figure 1.3). Below the critical concentration,
the monomer is the predominant species. As the protein concentration is
increased beyond the critical concentration, the polymer concentration continues
to rise, but the monomer concentration remains the same (Figure 1.3). The
critical concentration phenomenon reflects the cooperativity of nucleus
formation; formation of the nucleus involves a series of unfavorable equilibria
(the rate of these association steps could be fast or slow, both scenarios are
precedented), while the equilibrium constant which characterizes the growth
phase is very favorable (Kg>>Kn, Figure 1.2).33,34 The critical concentration is
equivalent to the growth equilibrium constant (Kg) and describes the solubility
of the protein under steady-state conditions.33,34
Seeded polymerization reactions require a
critical concentration of monomer.
t fibril
amount
I
monomer
CR - [protein] -
Figure 1.3: Fibril formation is concentration-dependent. Below the critical
concentration (CR), no fibril formation will occur. Above that concentration,
all added protein will be incorporated into the fibrils such that the monomer
concentration never exceeds CR. This behavior is seen at equilibrium.
Micelle formation also requires a critical concentration, referred to as the
critical micelle concentration (CMC). Amyloid fibril nucleation is much slower
than micelle formation, possibly due to the greater entropic barrier involved in
organizing a fibril.2 2 As a consequence, supersaturated protein solutions are
metastable, or kinetically soluble (see discussion of lag time below). By
definition, the kinetic solubility of an amyloid protein is time-dependent; at
infinite time, the kinetic solubility and the critical concentration are equivalent.
The kinetic solubility of amyloid proteins may play an important role in the in
vivo process leading to disease; this will be discussed in detail at the end of this
chapter.
AfP-40 has a slightly higher critical concentration than Apl-42. The critical
concentration is typically measured by determining the concentration at which
fibril formation and fibril dissolution are equal.33,35 The concentration of A3
remaining in solution after amyloid fibril formation should also equal the critical
concentration, provided that equilibrium33 has been reached. That concentration
should also be equal to the concentration of soluble material reached by
dissolving fibrillar AP. Two AB model peptides (AP26-40, A326-43) have been
analyzed in this way,36 but the full-length A3 variants have not.
Comparing literature reports of A3 critical concentration determinations is
difficult, since buffer compositions and methods for measuring monomeric AD
and fibrillar A3 vary. However, there is a qualitative consensus among
experiments performed under "physiological" conditions (pH 7-8, 5 -100 mM salt,
25-37 0 C): (1) A1l-40 rapidly forms amyloid fibrils at concentrations over 100
p~M, 19,37 (2) At Al1-40 concentrations between 20 jtM and 80 gM, a period of
kinetic solubility precedes fibril formation.9,11,23,38-40 Some researchers have
observed instantaneous aggregation in the latter concentration range, possibly
due to the presence of a small amount of undissolved seed fibril in the protein
stock solution (vide infra). Using complementary methods, the operational
solubility of Apl-40 has been measured to be ca. 35 jiM,23,4 1 6-9 iM,2 7 and 10 jM
(in 1M urea).35 Thus the critical concentration of A31-40 at neutral pH is ca. 10 -
40 gM, and significant kinetic solubility will be observed at concentrations less
than 100gM.
The AP variant AP1-42 has not been studied in as much detail as Al1-40
due to its limited availability42 and its greater insolubility.19,27,43 The difference
in critical concentration is demonstrated by the fact that the supernatant after
Apl-42 fibril formation contained four- to fivefold less soluble monomer
(interpreted as dimer in reference based on calibration of size exclusion elution
profile calibrated with globular proteins, a 4 kDa A3 monomer would likely
migrate with an apparent molecular weight of 8-9 kDa due to its nonglobular
structure--extended random coil proteins typically behave in this manner44) than
did the supernatant after Apl-40 fibril formation.45 At A31-42 concentrations as
low as 20-25 gM (37, 41), aggregation has been observed within the few minutes
required to make the initial measurement. This may be due to the difficulties
with the complete solubilization of the commercial material, (vide infra) leaving
seed fibrils in the stock solution. At 8 gtM Al1-42, significant aggregation has
been observed within 12 hours, but, since earlier time points were not measured,
the existence of a significant lag time cannot be ruled out.46 The post-
aggregation solubility of Apl-42 is difficult to accurately measure; reported
values between 2 and 15 gtM,27,46 reflect the intrinsic critical concentration of
Apl-42. Thus the critical concentration of Al1-42 appears to be in the low
micromolar range, ca. 5-fold lower than the critical concentration of A31-40.45
Apl-42 has shown little or no evidence of kinetic solubility.
Suggestions of an intermediate in Af fibril formation. Analytical ultracentrifugation
has shown that Apl-40, below its critical concentration (25 jiM), exists
predominantly as a monomer. 47 The same method indicated that, well above its
critical concentration (ca. 450 gJM), monomeric Apl-40 coexists with with
insoluble fibrillar high molecular weight oligomers. 37 In addition, slow-
sedimenting (operationally soluble) AI1-40 oligomers were detected. Based on
sedimentation properties, the molecular weight of the putative intermediate has
been proposed to be ca. 4,000 kD (an AD 1000 mer?). 37 An A3-apoE complex of
comparable size has been purified by gel filtration (see below).48 These findings
suggest that the actual mechanism for A3 amyloid formation may be more
complex than the simple model presented in Figure 1.2. Other A3 aggregates
have been detected under different conditions. The surfactant properties of A3
have been documented: both Apl-40 and A31-42 show surface activity at the air-
water interface, probably due to monolayer formation (critical concentration = 25
tM). A form of Al1-40 with behavior resembling that of a micelle (diameter
based on a spherical model = 14 nm) was detected by quasielastic light scattering
(QLS) studies of Apl-40 in 0.1 N aqueous HCl (CMC = 100 gM, critical conc. for
fibril growth under these conditions < 25 jM).49 It was proposed that these
species slowly convert into fibril nuclei. 49
How is the AP critical concentration exceeded in the AD brain? The concentration of
AD in cerebrospinal fluid is in the low nanomolar range.15 ,5 0 However, in vitro
amyloid fibril growth in single component AB 1-40 or A01-42 solutions has not
been detected at submicromolar A3 concentrations. In order for A amyloid
formation to occur in the brain, there must either exist a process whereby a local
AB concentration in the gM range is created, or the in vivo critical concentration
must be lowered by an endogenous substance. We will consider these
possibilities in turn. Two general mechanisms for local A3 concentration can be
proposed based on in vitro studies; (1) concentrate A3 in a cellular compartment,
(2) create a high effective concentration, for example, by A3 binding to
proteoglycan51 or directly to the membrane surface.4 7  Mechanism (1) is
consistent with cell-culture studies of A production from APP which
demonstrate the proteolysis may occur in a cellular compartment. 1 Lysosomal
pH clearly induces rapid A3 aggregation,3 7,38,43,52 but the low pH precipitate is
not fibrillar.38 Mechanism (2) is supported by the observation that phospholipid
vesicles lower the Apl-40 concentration required to observe a random coil-to-3-
sheet transition indicative of amyloid formation.4 7 In addition to mechanisms
that create a high local concentration of A in vivo, endogenous proteins or other
factors could lower the critical concentration of A3. The amyloid-associated
protein acetylcholinesterase (AChE), at a 1% relative concentration (2.4 jM
AChE vs. 240 jgM Apl-40), decreased the critical concentration of Apl-40
approximately 3-fold (at pH 5).53 The effect of AChE on the rate of amyloid
formation was not determined. In addition, endogenous metals may also lower
the A3 critical concentration. Zinc is capable of inducing precipitation of A at
subnanomolar A3 concentration, 54,55 although it has not been demonstrated that
the Zn-induced A3 aggregates are ordered amyloid fibrils.
Proteins and other molecules may raise the Af critical concentration. This effect,
which could be important in vivo, could be achieved by destabilizing the amyloid
fibril or by stabilizing the AD monomer. The amyloid-associated protein serum
amyloid P component (SAP, 2% by moles) was shown to increase the in vitro
critical concentration of AB1-42 by approximately three-fold (see discussion of
sedimentation assay below). SAP also inhibited A31-42 amyloid formation. 46
However, it is not necessarily the case that molecules which raise the critical
concentration would decrease the rate of amyloid formation (or vice versa, see
discussion of apoE below). Monoclonal antibodies raised against peptides based
on the AB sequence increase the A01-40 critical concentration (at equimolar
concentration vs. Apl-40), possibly by binding AB monomer.5 6 Analogs of the
antibiotic rifampicin (5% by moles) 9 and a long-chain alkyl piperidinium salt (ca.
10% by moles) 11 have similar effects. The detailed kinetic behavior of A3 in the
presence of these compounds has not been reported.
Lag Time
The length of time during which a supersaturated solution remains
kinetically soluble before amyloid formation commences is called the lag time
(Figure 1.4). During the lag time, small, but not necessarily detectable, amounts
of prenucleus oligomers sequentially build up according to the simplified
mechanistic scheme presented in Figure 2. The rate of nucleus formation is slow,
due primarily to the unfavorability of the preceding association equilibria, rather
than to the intrinsically slow association rates.34 The length of the lag time can
be extremely sensitive to protein concentration, depending on the oligomer size
of the nucleus and other details of mechanism which are unclear in the case of
AP. Extremely large concentration-dependences of the lag time for sickle-cell
fibril formation (ca. 25 - 50-fold) have been measured.5 7 The magnitude of the
concentration-dependence may be due to the coexistence of a secondary
nucleation pathway, which involves nucleus formation at the fibril surface. 58 A
similar phenomenon could exist in A3 amyloid fibril formation. The
concentration-dependences of the Al1-40 and Apl-42 lag times have not been
measured, due, in part, to experimental inconsistencies which are unavoidable at
the low concentrations of AD required to observe a significant lag time (see
below). However, a large concentration-dependence may not be seen if the
observed lag time for AB fibril formation arises from the slow conversion of a
relatively rapidly formed oligomeric intermediate form of AD to an ordered
nucleus.
Seeded polymerization reactions show a lag time.
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Figure 1.4 An idealized kinetic curve for amyloid formation, at a concentration
barely exceeding the critical concentration (CR). During the lag time, AP is
kinetically soluble.
Apl-40 is significantly more kinetically soluble than A/1-42. The critical
concentration of A1l-42 is only four- to five-fold greater than A01-40 (see above).
However, the kinetic solubility of A31-40 has been demonstrated to be
significantly greater than that of Apl-42.2 7 For example, a supersaturated
solution of A01-40 (20 gM) is kinetically soluble for days (lag time = 96 h),
whereas kinetic solubility has not been demonstrated for Apl-42 at the identical
concentration (lag time << lh).2 7 The difference in lag times could arise from a
stabilizing effect of the C-terminus on each step preceeding nucleus formation.
However, this possibility should not be overemphasized, since A01-42
amyloidogenesis may follow a pathway that is mechanistically distinct from the
+:L I. ,I
Apl-40 pathway. Resolution of this issue will require the direct comparison of
the Apl-40 and AP1-42 mechanisms, using multiple techniques.
ApoE inhibits amyloid nucleation. ApoE2 and other endogenous proteins which
inhibit amyloid formation may protect against AD. There are three isoforms of
human apolipoprotein E, apoE2, apoE3, and apoE4. ApoE2 and apoE4 differ
from apoE3 at a single residue (out of 299). The E3 allele is the most widespread,
followed by E4 and E2. ApoE4 homozygotes have a significantly increased risk
of contracting AD, at an earlier age, than do apoE3 homozygotes. 5 9 ApoE2
homozygotes, though very rare, seem to be protected against AD.5 9 The apoE2
allele is underrepresented (and the apoE4 allele is overrepresented) in the AD
population, implicating ApoE2 as a protective factor against AD.5 9 ApoE4-
bearing AD patients have a high amyloid burden at the time of death as
compared to the average AD patient.60 Thus, apoE4 may promote amyloid
formation relative to apoE3. This phenotype could result either from apoE4
being a better amyloid promoter than apoE3,25 ,26 or from apoE4 being a less
efficient amyloid inhibitor than apoE3.23,24,61,62 Experimental support for both
of these scenarios has been presented. The inhibitory scenario is supported by
the fact that apoE3, at molar ratio of 0.1% to 1% as compared to Apl-40,
significantly increases the observed lag time.23,61,62 The apoE3 dimer is a much
more potent inhibitor than monomeric apoE3 or monomeric apoE4 (apoE4
cannot dimerize). 23 Based on these results, a mechanistic model, in which apoE
binds to a prenucleus AP oligomer, was proposed.23 Recently other laboratories
have confirmed the inhibitory activity of apoE3 24,61,62 and isolated an apoE-A3
oligomer.6 1 This complex was not an effective seed of AP polymerization, rather,
it was an inhibitor of AP seeding.6 1 ApoE3 inhibits amyloid formation when
coexpressed in doubly transfected cell cultures, and attenuates AP fibril-induced
neurotoxicity.63,64 Finally, the observation that plaques in apoE4-bearing
individuals were more numerous, yet no larger than plaques in apoE3
homozygotes, suggests that the inhibitory effect is focused on the initiation of
plaque formation.65 Earlier studies, which led to the proposal that apoE4
promoted amyloid formation, were based on single time point measurements of
amyloid using a method not suited for the quantitation of amyloid (see
below).25,26
Seeding
At concentrations above the critical concentration, the slow nucleation
step can be bypassed by the introduction of exogenous nucleus or seed.34 As a
consequence of seeding, the Al1-40 lag time is eliminated and a first-order
growth process occurs (Figure 1.5).35,49 ,66,67 Seeding of amyloid formation, like
seeding of a crystallization, is extremely discriminating, since it relies on a
complementarity between the growth face of the seed fibril and the substrate. 68
However, as is the case in the growth of inorganic crystals, a seed of a different
constitution can function as a heterogeneous seed, provided that its growth face
is complementary to the native substrate. Both homogeneous and heterogeneous
seeding may be important in accelerating amyloid formation in AD.
Seeding eliminates the lag time.
Figure 1.5 Amyloid formation can be seeded. Under conditions where kinetic
solubility is observed (Figure 1.4), the addition of a seed will reduce or
eliminate the lag time and induce immediate fibril formation.
Amyloid formation by AP1-40 is seeded by A[1-40 fibrils, AP1-42 fibrils, and NAC
fibrils. Addition of preformed fibrillar AB1-40 to unseeded solutions of A11-40 at
concentrations barely exceeding its critical concentration can reduce6 1 ,62
(addition of ca. 0.02% by weight) or eliminate2 7,6 1,62 (addition of ca. 5-10% by
weight) the observance of a lag time. AP1-42 fibrils are also efficient
heterogeneous seeds for A polymerization. 27,37,38 The initial observation of this
effect led to the proposal that seeding of amyloid formation by A1-42 may be a
mechanism of familial early-onset AD (FAD).27 Subsequent information from
neuropathological studies supports the feasibility of this proposed mechanism to
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explain several forms of FAD (involving mutations on chromosomes 1, 21, and
14).8,17,18
The 35-amino acid peptide NAC (Non AP component of AD amyloid) is
an intrinsic component of the insoluble fibrillar core of AD amyloid. 6 9 This
peptide contains an eight amino-acid sequence which is very similar to the
critical C-terminus of the Al1-42 and a sequence in the prion protein, a brain
amyloid protein implicated in scrapie. 70 NAC amyloid fibrils are efficient seeds
for amyloid formation by Apl-40.70 Conversely, A31-40 fibrils efficiently seed
amyloid formation by NAC. 70 This in vitro activity suggests that NAC may
trigger AP aggregation in vivo or, alternatively, may be a target of an AB
oligomeric seed.70
MEASURING AMYLOID FORMATION IS DIFFICULT
The studies of AP aggregation discussed above all suffer from a major
experimental problem, that is, the lack of a single accurate method to quantitate
amyloid fibrils and, especially, to compare fibrils formed under different
conditions. Amyloid is not well understood at the structural or morphological
level;2 1,22 in fact, the existence of more than one type of amyloid fibril suggests
that there may be more than one conformational state or packing arrangement
for AP in amyloid. 71,72 Amyloid has, therefore, been defined operationally as an
insoluble fibrous protein aggregate with affinity for Congo red (CR) and
thioflavine T (thioT).2 1  None of these individual properties is unique to
amyloid. Therefore, no single property should be the basis for a quantitative
assay. Instead, a combination of methods must be used to increase the specificity
of the measurement. The value of this approach is clearly demonstrated in a
study of the pH-dependence of AP amyloid formation.38 It has been widely
reported that the pH maximum for AD aggregation is in the 5-6 range,19,3 7,43 ,52
suggesting that in vivo amyloid formation may take place in the lysosome.
Sedimentable Apl-40 aggregates grown under unstirred conditions at pH 5.8 and
at pH 7.4 bind to CR and thioT but are clearly different.3 8 First, the aggregates
formed at pH 5.8 bind more CR on a molar basis than do Al1-40 aggregates
formed at pH 7.4 3 8 Second, the pH 7.4 A31-40 aggregates are fibrillar (as shown
by EM) but do not exhibit turbidity at 405 nm, while the turbid aggregates
formed at pH 5.8 do not appear to be fibrillar by EM (although they induce a
significant enhancement in the thioT fluorescence emission spectrum).3 8 Third,
the aggregates grown at pH 5.8 are unable to seed polymerization of A31-40 at
pH 7.4.38 The two aggregate morphologies do not interconvert when incubated
under the conditions used to grow the alternate morphology.38 The existence of
distinct AB amyloid morphologies could add considerable complexity to the
idealized mechanism depicted in Figure 1.2.
Existing Methods Have Complementary Strengths and Weaknesses
The commonly used methods for identifying and quantitating amyloid
will be briefly discussed below.
Electron microscopy. EM is useful for identifying amyloid fibrils and describing,
at low resolution, their morphology. However, it is not possible to quantitate the
amount of amyloid protein in fibrillar form by this method. Attempts have been
made to utilize the number of fibril crossovers per field to quantitate total
amyloid,2 6 however, in our experience, it is difficult to select a "typical" field for
fibril counting due to clumping of the fibrils. Fibril-fibril associations could alter
the amount of crossovers in selected regions (as compared to an ideal
homogeneous distribution of straight fibrils) without affecting the total amount
of fibrillar protein. Finally, it is impractical to follow a kinetic run by EM, since
sample preparation (fixing, staining, etc.) is time-consuming and may affect fibril
morphology.
Turbidity. Turbidity detects all particles with a hydrodynamic radius greater
than the wavelength of the incident light (e.g., 400 nm).7 3 For a homogenous
population of fibrils, turbidity correlates with oligomer size. 73 The following
findings suggest that turbidity alone is not sufficient to quantify the total amount
of fibrillar protein: (a) Turbidity is not specific to amyloid fibrils.38 (b) The total
turbidity will depend on the aggregate morphology (in a nonobvious way).38 (c)
Early intermediates in the fibrillization process may be too small to be detected.73
For example, the fact that AChE increases the final turbidity of Al1-40 by three-
fold could be explained in at least two ways: either AChE decreases the Apl-40
critical concentration or it induces a morphological shift to a fibril type which
produces more turbidity.53 An independent measurement of the amount of AP1-
40 remaining in solution after sedimentation of fibrils supports the former
scenario. 46,53 Any study using turbidity as a quantitative measure of amyloid
should confirm the legitimacy of the method using an independent method to
assure that a morphological shift has not occurred. 38,40
Sedimentation. Separation of the soluble monomeric protein from the insoluble
amyloid by centrifugation and/or by filtration has been attempted. However,
sedimentation does not distinguish ordered amyloid (the morphology of interest)
from insoluble amorphous aggregates. For example, 100 mM Zn induces
precipitation (measured by sedimentation) of A11-40 at subnanomolar
concentrations; a decrease in the solubility of A3l-40 by 106 -fold.55,74 This work
does not differentiate between zinc-induced amorphous aggregation and zinc-
induced amyloid formation. Finally, sedimentation may not be able to separate
ordered oligomers with low molecular weights (compared to fibrils) from AP
monomer. Soluble A3 oligomers, which may be important intermediates in
amyloid fibril formation, have been observed in two studies.37,45
Birefringent Congo red binding. Birefringent CR binding, a defining property of
amyloid fibrils, requires that the binding sites be ordered with respect to one
another, as may be the case along the surface of an ordered aggregate. 21 Bound
CR can be quantitated because there is a spectral shift on binding.38,75
Unfortunately, CR birefringence cannot be quantified in the same way as CR
binding can, so it is not possible to determine what portion of the CR-protien
complex is fibrillar. Thus the conclusion, based on CR birefrengence, that 25 gM
A1-40 forms amyloid, as opposed to amorphous aggregate, in the presence of
equimolar zinc54 requires confirmation by another method.
Thioflavine T-induced fluorescence. The induced fluorescence of thioT has been
widely applied to study amyloid formation, because of its sensitivity and
practicality. 24,35,76,77 Fluorescence enhancement is assumed to be common to
amyloid fibrils, but this generality has not been demonstrated, and magnitude of
this effect has been shown to vary as a function of A3 1-40 aggregate
morphology. 38 Furthermore, there is also evidence that thioT binds to soluble
oligomers of Ap. 78 In addition, the magnitude of the induced fluorescence
emission depends on the morphology of the aggregate. 38 Consequently, the
thioT fluorescence assay should not be used to compare fibril growth under
conditions that vary slightly, unless it is shown independently that these changes
do not result in a morphological change in the aggregate.
Quasi-elastic light scattering. QLS directly measures the diffusion coefficient of a
species in solution.4 9,79-82 The diffusion coefficient is related to hydrodynamic
radius and, depending on the shape of the species, to molecular weight. Thus if
complementary information about aggregate morphology is available from EM
or atomic force microscopy (AFM), the kinetics of amyloidogenesis can be
measured. 4 9 Also, since multiple species can sometimes be simultaneously
detected and distinguished (depending on their relative size), some low
molecular weight species may be identified and quantified with this method.49
Atomic Force Microscopy. AFM is a method of imaging material on surfaces with a
resolution currently comparable to electron microscopy. 7 1, 72  Recent
technological advances may provide a significant increase in AFM resolution of
biological features. 83 However, unlike EM, AFM requires little or no sample
preparation and can, in some cases, be used to image species in buffer in a
continuous mode, which is ideal for kinetic studies. This method has
demonstrated a morphological heterogeneity of AP amyloid fibrils which is not
readily apparent from negative stain EM analysis (often because of the variability
of the staining procedure). 71,72 AFM offers the potential to simultaneously study
the morphology and assembly kinetics of a single fibril provided that suitable
binding to substrate can be achieved. Since AFM imaging ordinarilly requires
non-specific adsorption of species to an atomically smooth surface (e.g., mica),
studies using AFM must control for the effect of the adsorption process on
aggregate morphology and/or assembly.
The Purity and Aggregation State of Synthetic AO Substrates Influences the
Kinetics of Amyloid Formation
The synthesis of insoluble proteins, such as the AO variants, is extremely
difficult. A typical solid-phase synthesis will average ca. 99.5% yield per
coupling. However, at the completion of a 39-step process, the crude product
will contain a significant amount of 39-mers, each missing a single amino acid.42
These deletion impurities can be extremely difficult to separate from the desired
product and, to make matters worse, can be extremely difficult to detect, since
each single deletion impurity constitutes less than 1% of the crude mixture.
However, these impurities could have a significant effect on the aggregation
kinetics, possibly acting as crystal poisons. 34 For example, the inhibitory effect of
Apl-40 on Apl-42 aggregation has been reported.3 7  In addition to chemical
impurities, it is important to eliminate "structural impurities" from the AO
substrate. A very small amount of preexisting ordered aggregate in a stock
solution may be capable of seeding polymerization of the AP protein.2 7,61,62,68
Extensive precautions should be followed to remove any aggregated A3 from
commercial lots before kinetic experiments are attempted.23,81
Stochastic Variability of Kinetic Experiments is Unavoidable
The timing of an improbable event like homogeneous nucleation is
difficult to predict and measure reproducibly. This experimental limitation has
been encountered in studies of sickle-cell hemoglobin polymerization.5 8,84-8 6
Finally, there are many variables (e.g., tube surfaces, stirring rate) which are
known to influence nucleation and growth but are extremely difficult to control.
PHYSIOLOGICAL CONSEQUENCES OF THE SEEDED POLYMERIZATION
MECHANISM
The ordered aggregation of AD follows a nucleation-dependent pathway,
which means that both protein concentration and time are important in
predicting their aggregation state. Since the "intrinsic" critical concentration of
AB, measured in vitro, is ca. three to four orders of magnitude greater than the
average brain concentration, a local supersaturation mechanism must exist in
order for the A3 nucleus to form and grow. The factor responsible for the local
supersaturation event may be unique to AD (e.g. overexpression of an abnormal
proteoglycan).5 1 However, the prevalence of sporadic AD which has no
relationship to known genetic abnormalities suggests that concentration can also
be the result of a process to which the protein is normally exposed. It is possible
that A3 is normally exposed, for times too short to allow nucleation, to a local
concentration exceeding its critical concentration. A slight increase in the local
concentration of A during that time could result in immediate intracellular
aggregation. This scenario may explain the early age of AD onset in Down
syndrome patients who overproduce A. At least two other variables that are
unique characteristics of the nucleation-dependent mechanism may play a role in
vivo. First, since kinetic solubility is, by definition, metastable, the time during
which the protein is locally concentrated is critical (Figure 1.6). Dilution of
protein before nucleus formation (t < lag time, Figure 1.6, arrow A) may reflect
the normal course of events. However, dilution of AB after nucleation (t > lag
time, Figure 1.6, arrow B) will result in the release of fibrillar material. Although
fibrillar AB will be far below its critical concentration, the slowness of
disaggregation may allow the fibril to be irreversibly trapped, or "fixed", leading
to its deposition in amyloid plaque.
TIME may be a critical factor for in vivo amyloid formation.
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Figure 1.6 Amyloid formation in vivo must involve a local concentration step.
The critical concentration of A3 must be exceeded, at least temporarily, so that
amyloid formation can occur. This step may be part of a normal cellular
process. In that case, the time at which this metastable concentration is
maintained may normally be short enough that aggregation does not have a
chance to occur (arrow A). If that time is lengthened in the disease, then
aggregation will have a chance to occur (arrowB).
Clearly, endogenous molecules could be very important in slowing
disaggregation, accelerating fixation, or both. It is also critical to identify the
mechanism of local supersaturation (compartmentalization, surface-binding, etc)
that allows nucleation to occur. Once this mechanism has been identified, it will
be critical to study the factors which control the duration of local
I
supersaturation. It is not difficult to imagine that some of these factors (e.g.
protein trafficking time) may be sensitive to age, the strongest risk factor for AD.
Seeding must occur in a supersatured locale.
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Figure 1.7 Seeded polymerization of AP must occur in a locally concentrated
environment, where the critical concentration has been exceeded. Both
homogeneous and heterogeneous (black seed) seeding may occur.
Another feature of the nucleation-dependent mechanistic model which
may have physiological consequences, is the seeding of a locally supersaturated
solution to induce immediate aggregation (Figure 1.7). Seeded growth can only
occur in the locally concentrated state. In the case of AD aggregation in AD,
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NAC fibrils could also induce polymerization of Apl-40 by heterogeneous
seeding.70
Despite our relative ignorance, the general features of the nucleation
dependent mechanism offer insights into the in vivo amyloid formation process.
However, much work remains to be done in order to completely characterize the
molecular mechanism of ordered AP aggregation in vitro. The structural and
morphological features of the aggregates are only beginning to be probed in
detail.2 1,38,71 In addition, the operationally soluble oligomeric species have been
detected using analytical ultracentrifugation 3 7 and QLS 4 9 The simplest form of
the nucleation dependent model does not predict the presence of significant
amounts of oligomeric A3 preceding fibril formation, and so the detection of
these species suggests that the actual pathway to fibril formation may be
considerably more complex. Furthermore, most of the methods that have
previously been used to follow the kinetics of amyloid formation are not capable
of adequately addressing the potential role that these species may play as
intermediates in amyloid fibril formation. The work that will be described in the
remainder of this thesis has been inspired by these indications of additional
complexity and has focussed on developing and applying new AFM
methodologies to test and refine the nucleation dependent model for amyloid
formation reviewed in this chapter.
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Chapter 2
Observation and Characterization of Transiently Populated
Oligomeric Intermediates in AP Fibril Formation
The presence of amyloid fibrils, ordered protein aggregates comprising
A3 protein variants, in the brain is a defining feature of AD. Because it is very
difficult to reconstruct the in vivo pathway based on neuropathological data, our
lab studies the in vitro mechanism of A3 amyloid formation on the assumption
that it may be analogous to the situation in AD. These initial in vitro studies led
to a mechanistic model of amyloid formation as a nucleation-dependent
polymerization that offers a plausible explanation for FAD.1-3 However, details
of the early steps in the in vitro mechanism have proved elusive because the
methods most commonly used to measure the time course of amyloid formation
(turbidometry, sedimentation, CR binding and thioT fluorescence) share two
significant limitations. First, these methods do not distinguish between or detect
all aggregate morphologies, so a single product morphology has been tacitly
assumed. Second, these methods are unable to detect small A3 oligomers, so
the early steps of the assembly process have not been elucidated.
We sought a method which would allow us to observe and characterize
any small A3 species that might be present during the early stages of aggregation
prior to fibril formation. AFM appeared to have the potential to provide this
information since it is capable of directly detecting and measuring with
nanometer scale resolution the dimensions of small proteinaceous species that
are adsorbed from aqueous media.4,5 Previous studies have demonstrated the
ability of AFM to distinguish multiple AB fibril morphologies and suggest that
fibril formation follows a more complex pathway than previously thought.6-9 By
using less destructive AFM imaging modes 4 and carefully examining the time
course for the formation of these morphologies, we believed that it would be
possible to improve the morphological characterization of these species and
establish their temporal relationship. This additional information is necessary to
begin to elucidate the molecular events that occur during AP fibril formation.
In the experiments described in this chapter we used AFM to follow the
aggregation of the two predominant AD variants at concentrations slightly in
excess of the critical concentration for amyloid formation (we used [Ap1-40] =
45-50 gM, compared to reported critical concentrations (solubilities) of Apl-40 of
ca. 10-40 gpM (35 gM, 10,11 6-9 gM,1 , and 10 gM (in 1 M urea) 12; and we used [AP1-
42] = 20 gM, compared to reported critical concentrations of A1l-42 of ca 2-15
gM1,13. These concentrations were selected on the grounds that these conditions
should approximate as closely as possible the in vivo amyloid formation in most
types of AD and should result in the slowest time courses for in vitro fibril
formation. Maximizing the time prior to the nucleation should also maximize
the opportunity to observe potential pre-nucleation intermediate species.
For both AB1-40 and A1l-42, the first-formed species were not the
amyloid fibrils. Instead, much smaller oligomeric species were observed,
including an elongated, apparently structured, morphology with constant
diameter. These elongated features gradually increased in length with time
(rarely exceeding 200 nm in length), then they rapidly disappeared in favor of
typical amyloid fibrils (usually > 1 gM in length). We refer to this transiently
observed species as the AP amyloid protofibril, to indicate the possibility that it
represents a fibril assembly intermediate. The overall process was much more
rapid in the case of the 42 amino-acid variant A01-42 when compared with the
truncated variant AP1-40 consistent with the fact that increased expression of the
former variant is associated with early-onset AD.
Atomic force microscopy
AFM is a physical imaging technique.
Atomic force microscopy (AFM) creates images of surfaces by measuring
the position of a sensitive cantilever with a silicon probe tip as a sample is moved
underneath (Figure 2.1). The AFM can be operated in several modes, with the
most common modes being the contact mode and the tapping mode. In the
contact mode (the first AFM imaging mode developed), the tip remains in
constant contact with the surface during a scan. This works very well for hard
surfaces, which resist compression and damage due to lateral shear forces
generated by the sweeping motion of the tip. However, biomolecules adsorbed
to substrates for imaging do not always withstand these forces well and can be
deformed or swept off the surface in this mode of operation. In the tapping
mode, the cantilever is oscillated at its resonant frequency (60-400 kHz
depending on the cantilever) and positioned above the sample so that it contacts
the surface briefly at the bottom of its swing. The time the tip contacts the
surface is very short when compared to the time required to trace across the
surface. As a result, shear forces are almost completely eliminated making this
mode of imaging better suited for imaging biomolecules.
In all imaging modes, the position of the sample under the tip is precisely
controlled by a piezoelectric ceramic-based scanner which can reposition the
sample under the tip in three dimensions in angstrom scale increments. Keeping
track of the movements required to raster the sample underneath the tip while
maintaining a constant deflection (contact mode) or oscillation amplitude
(tapping mode) at each position in the region results in an digitized topograph of
the surface. Visual representations of this data can then be generated by
assigning each point in the area a color or brightness based on its relative height.
For images in this thesis, the smooth surface of the mica substrate will appear
dark gray with the brightness of the adsorbed features increasing as a function of
their height.
position
sensitivelaser detector
cantilever
with
sharp tip sample on
- very smooth
substrate
Figure 2.1: Schematic diagram of an atomic force microscope.
Interpretation of lateral dimensions.
The resulting topographical data for the area can also be used to obtain 3
dimensional measurements of adsorbed features with a high degree of precision,
but it is important to consider several limitations which arise as a result of the
physical nature of the technique when discussing dimensions measured by AFM.
In general, the height of an object above the surface can be determined, but the
lateral dimension in the plane of the image (the width) is difficult to measure
accurately, due to the shape and the finite size of the tip(Figure 2.2). The
overestimation of width is related to the height and true width of the feature and
the shape of the 5 - 10 nm diameter silicon tip, which is difficult to accurately
determine. 4 Consequently, we use measurements of the height rather than the
width as estimates of the diameters of A3 aggregate species, although the cross-
section may not be circular or square (see discussion of morphologies below).
Observed Image
Tip _
Figure 2.2 AFM tip shape influences lateral dimensions. The schematic shows
a stylized representation of tip-sample interactions for a pyramidal tip
representing the silicon probes used in these experiments. The edge of the tip
contacts the feature prior to the apex, prematurely deflects the cantilever, and
increases the apparent lateral dimensions in the observed image (solid line at
right). Note that the height of the feature is much more accurately represented.
Interpretation of height measurements.
There are a number of reasons why the height of features measured by
AFM in air may underestimate the actual diameters of features as they exist in
solution:5 1) The force applied by the cantilever may compress soft biological
features. 2) Dehydration of the protein following the removal of buffer prior to
imaging could reduce measured dimensions. 3) Height measurements may be
reduced if features deform during the adsorption process to maximize the
surface area of contact to the substrate (similar to the deformation that results
when a spherical water droplet adheres to a surface). Differences in cantilevers,
tips, instrument parameters, and/or sample preparation conditions can result in
variability in the measured dimensions of the same species in different scans.
Therefore, comparisons of height between morphologies are made, when
possible, from single images clearly resolving both species. This is done to
ensure that variability in measurements among scans does not cause the relative
dimensions of morphologies to be misrepresented. When this is not possible the
diameter of a distinct morphology present with each species is used as a
reference to allow comparisons of their relative heights to be made with more
confidence (for example, protofibrils are generally not observed in the same
specimen with type 2 fibrils, but standardization of their diameters relative to
type 1 fibrils commonly present alongside each species can be used to compare
their heights).
Specimen preparation.
To prepare specimens for imaging, aliquots of protein
solutions/suspensions are applied to the atomically smooth surface of freshly
cleaved mica and allowed to incubate (typically for 30 seconds to several
minutes). Following incubation, excess protein and buffer salts are rinsed away
with water and the material that remains bound to the mica surface is analyzed
by AFM. Because all aggregate species may not be equally well adsorbed, it is
not possible to quantitate the relative amounts of species present in solution
based on their abundance on the mica substrate, nor is it possible to rule out the
existence of additional species that might be very poorly adsorbed. There is little
reason to suspect, however, that the ability of a species to adsorb will change
with time. Therefore, the relative amounts of a species observed (using the same
specimen preparation) at each time point during an experiment should provide
reliable qualitative information about the changes in abundance of a particular
morphology during the course of aggregation.
Evolution of aggregated species observed by AFM
A31-40 rapidly formed discrete protofibrils.
We prepared Apl-40 solutions for analysis by AFM using essentially
identical conditions to those used previously in this lab for turbidity based
investigations of amyloid formation. 11,14 Briefly, concentrated stock solutions of
the peptide (in this case Apl-40) were made in DMSO, and aliquots of the stock
solution were added to buffer (10 mM Phosphate, 100 mM NaCl, pH 7.4) to
achieve the desired final peptide concentration. Solutions were incubated
without agitation at room temprerature. At the indicated times, each of these
A11-40 solutions were briefly vortexed to evenly suspend any aggregates which
may have precipitated before aliquots were removed and placed on a freshly
cleaved mica surface. After brief (0.5-2 min.) incubation on the mica surface
under ambient conditions, filtered ultrapure water was used to gently rinse away
excess protein and buffer salts, and the structural properties of the species
adsorbed onto mica were analyzed immediately by AFM.
The top panel of Figure 2.3 shows a representative time course for the
aggregation of Apl-40 (45 [tM). In each image, the mica surface appears dark
gray, and the brightness of the features increases as a function of their height.
After four days, the adsorbed material consisted mostly of small species with
uniform diameters of about 4 nm (the measured heights of features will be
referred to as diameters herein, although the cross-section may not be circular or
square). There were also a few larger globular features with diameters ranging
widely between 13 - 23 nm (larger bright white spots in image). Some of the -4
nm diameter features at 4 days appeared to be roughly spherical while many
others were clearly elongated with lengths between 40-60 nm being the most
common. We will refer to these - 4 nm diameter species as AP amyloid
protofibrils (to reflect their early appearance before the observation of
prototypical A3 amyloid fibrils and the possibility that they represent a fibril
assembly intermediate, see below). The protofibrils elongated over three weeks
while retaining a constant diameter, commonly reaching lengths of 100 - 200 nm.
A parallel incubation with a much higher Apl-40 concentration (200 gM)
developed protofibrils of comparable length in two days (data not shown, the
concentration dependence of protofibril formation will be discussed in more
detail in chapter 3). The small size of these protofibrils precludes their
observation by turbidity measurements at 400 nm (unless they become
associated in large aggregates).
Af31-40
4 da s 3 weeks 4 weeks 5 weeks
SAP31-42
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Figure 2.3 Representative AFM images of the time course of fibril formation.
Images are of A01-40 (at 45 gtM, top row) and A01-42 (at 20 pM, bottom row).
All images are 2 pm square.
Apl-40 protofibrils disappeared, concurrent with the appearance offibrils.
After four weeks of incubation, the first long (typically > 1 pm) Af1-40
species resembling prototypical amyloid fibrils appeared (designated type 1
fibrils since they were the earliest type of fibrils to be observed). Type 1 fibrils
had a beaded appearance indicating periodic modulations in height which
reached maximum diameters of approximately twice the diameter of the
protofibril (detailed measurements below). Strikingly, short (< 500 nm) type 1
fibrils were rarely seen. After five weeks, the protofibrils had disappeared
completely and a second fibril type (type 2 fibril) appeared which had a smaller
diameter than the type 1 fibril and was characterized by a segmented rather than
a beaded appearance.
Rapid assembly of AP1-42.
Amyloid fibril formation by Apl-42 followed a similar, but accelerated,
time course (Figure 2.3 bottom) compared to Apl-40 producing analogous
intermediate species and fibril morphologies. The accelerated time course was
observed despite the fact that the Apl-42 concentration in these experiments was,
as it is in vivo, 15 significantly lower (20 jiM) than the A31-40 concentration (45
jrM). Protofibrils formed within the first day of incubation and elongated over
the next eight days. Long (almost always > 1 gim, usually > 5 gm) AP1-42 type 1
and type 2 fibrils were detected after 8 days of incubation and all protofibrils had
disappeared by 11 days. The observed kinetic differences between Apl-42 and
Apl-40, which are consistent with previous turbidometric studies in this lab,1
support the proposal that elevated levels of Al1-42 lead to more rapid amyloid
formation in early-onset familial AD (FAD).1,16 This scenario has been
supported by numerous studies of the levels of AP1-42 and Apl-40 in the
plasma 15 and brain tissue17,18 of FAD patients and in the culture media of cells
stably transfected with FAD mutant gene products.
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For both Aj1-40 and Apl-42, the transient population of small oligomeric
intermediates prior to the appearance of fibrils is clear. Small oligomeric A3
species have also been separated and/or detected by other methods. Analysis by
analytical ultracentrifugation of A 31-40 (450 gM) detected a slowly sedimenting
species (proposed to contain -1000 Al1-40 molecules), which was observed in
addition to the rapidly sedimenting, probably fibrillar material. 23 Dynamic light
scattering of AP31-40 aggregation under acidic conditions detected the rapid
formation of an oligomeric Al1-40 species (diameter based on a spherical model
= 14 nm), proposed to be a micelle (critical concentration in 0.1N HCI = 100
itM).24 Small globular and elongated species have also been observed previously
by AFM, but rather harsh modifications were required to achieve stable contact
mode imaging of these features (imaging under isopropanol6-8 or coating with
platinum carbon 9 ). The absence of a kinetic component to these AFM
experiments left the relevance of these species to fibril formation in aqueous
conditions unresolved.
Of particular relevance is the analysis of the initial stages of fibril
formation using gel filtration chromatography. Walsh et al. showed that both
Apl-40 and Al1-42 (at 220 pM) produce slowly sedimenting species that eluted
from a size exclusion column with an estimated MW > 100 kDa. 25 Negative stain
EM analysis of these high molecular weight fractions revealed curved fibrils 6-8
nm in diameter and < 200 nm in length which they also call protofibrils. 25 The
results of Walsh et al. also show that there is a time dependent increase in the
amount of material that correlates with the increase in protofibril length with
time that we have observed by AFM.2 5 Furthermore, the kinetics of protofibril
formation and disappearance (observed by the time dependent increase and then
decrease in the magnitude of the protofibril containing peak) also confirm that
this species is only transiently populated during fibril formation.25
Description of aggregate morphologies.
Images produced during numerous experiments were screened to find
well resolved images clearly displaying the morphologies observed during the
aggregation of A31-40. Although aggregation conditions (including time, [A01-
40], temperature) were not always identical for each image chosen, these
alterations have not been observed to affect the measured dimensions for Apl-40
aggregate morphologies.
Globular particles
Well resolved images of A31-40 samples obtained at early time points
regularly show numerous globular features with diameters ranging from -1 nm
to 20 nm or more. These features are more commonly observed at lower
concentrations of A1l-40 (< 50 gM) and become less common as fibril formation
proceeds. Figure 2.4 shows a representative image and cross sections of these
globular species from a 16 gM solution of Al1-40 2 days after dilution and
incubation at RT and from a 45 CiM solution 4 days after dilution.
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Figure 2.4 Representative image and sections of A01-40 globular particles.
TOP: A 250 nm image of Apl-40 (16 pM) after 2 days of incubation at room
temperature (left) with sections along the indicated lines (right). BOTTOM: A
500 nm image of A01-40 (45 pM) after 4 days of incubation at room
temperature (left) with a section along the indicated line (right) showing an
example of a large globular aggregate. Red and green arrowheads in the image
correspond to the similarly marked features in the sections shown at right
where the heights are indicated.
A representative region (300 x 300 nm2 ) was selected from the image of the
16 gM AB1-40 solution and the diameter of each globular feature present in that
region was measured (for the more numerous ~1 nm features, a 150 x 150 nm
region was analyzed and the frequency of heights was scaled appropriately to
represent the larger region). The frequency distribution of the diameters was
examined and is shown in Figure 2.5. Clear maxima are observed at -~1.5 nm and
~4.5 nm and a much less populated peak between 7-11 nm. Only two features in
the 8-10 nm diameter range were in the counted area--there were 8 features
between 7 and 11 nm in a 1pm square region on the same specimen. At higher
concentrations and incubation times (for example, A1-40 at 45 gtM after 4 days--
Figure 2.4, bottom) even larger globular features with diameters of 15-20 nm are
sometimes observed. The coincident distribution of diameters measured for
protofibrils present in the same region with the distribution of the -4.5 nm
globular species suggests that these features may be related (ie. the 4.5 nm
particles may be short protofibrils, or protofibril assembly subunits).
Comparison to globular particle sizes observed on a different specimen prepared
with buffer alone (at same concentration present in AD solutions) indicates that
the 1.5 nm particles can be observed with significant frequency without A31-40.
The presence of the ~1.5 nm species in buffer makes it uncertain whether the 1.5
nm species is related to AD, but the significant increase in frequency when A01-
40 is present suggests that some of these particles may be AP-derived.
The presence of multiple maxima in the distribution suggests that there
are multiple distinct globular features with quantized sizes. The decreasing
frequency of each consecutive peak of increasing diameter is what one would
expect to observe if these species represented oligomers formed by sequential
addition of a precursor species of discrete size (the aforementioned problems
associated with adsorption density comparisons could also explain this
observation).
Similar indications for multiple small distinct A3 assemblies have been
reported using and AFM6,7,9 and quasi-elastic light-scattering.24,25 The smallest
Al1-40 particle directly detected by light scattering at pH 1.0 had a
hydrodynamic radius of 7 nm.24 Extrapolation of the linear phase for fibril
growth back to t = 0 in the same pH 1.0 experiments predicts the presence of a
smaller particle with a hydrodynamic radius of 4 nm.24 When Walsh et al.
examine the included peak from their size exclusion separation of A1l-40
aggregates under conditions more closely resembling our own (at pH 7.4), they
are able to detect particles with an even smaller hydrodynamic radius = 1.8 ± 0.2
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Figure 2.5 Distribution of globular aggregate diameters observed in an AP1-40
solution (16 gM) after two days. Frequency number represents the number of
individual features with the indicated height/diameter range in a 300 x 300 nm
area (protofibril frequency does not represent the number of individual
species because multiple diameter measurements were made along each
protofibril). Arrows point to larger features present with very low frequency
on mica.
nm (interpreted to be consistent with monomeric or dimeric Apl-40).25
Although these independent indications of multiple globular species were
obtained under very different conditions, our results are also consistent with the
presence of several very small forms of AP during (and possibly preceding) the
formation of protofibrils. The use of recently developed nanotube AFM probes
should significantly improve resolution of these features.2 6
Protofibrils
Protofibrils are also present at very early time points but appear to be
more ordered assemblies of AP than globular species because their growth
occurs essentially in one dimension instead of three. Instead of expanding
equally in all directions to form larger spheres they incorporate peptide
selectively into one or both ends (of an imaginary cylinder) so that the length of
the protofibril increases while it maintains a roughly constant diameter. Figure
2.6 shows a representative image and cross sections of protofibrils from a
previously undisturbed (no prior sampling & therefore no prior tapping to
suspend aggregates) solution of AB1-40 (45 gpM) 8 weeks after dilution and
incubation at RT. This sample was identical in Al1-40 concentration and peptide
stock source yet contained only protofibrils. The only apparent difference
between these samples was the lack of aggitation. The slower progression
toward fibrils observed for this sample (and numerous others) is consistent with
previous observations using turbidityll ,27 and congo red binding 28 to follow AP
aggregation which showed that aggitation significantly increased aggregation
kinetics in Apl-40 solutions.
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Figure 2.6 Representative image and sections of Afl-40 protofibrils. Red and
green arrowheads in the 1 pm square image correspond to the similarly marked
features in the sections shown at right. TOP RIGHT: An axial section of a
protofibril showing 56 nm total distance between arrowheads indicating three
periods in the axial substructure of the protofibril. BOTTOM RIGHT: A cross
section of protofibril indicating the 4.4 nm measured diameter of this
representative feature.
In general protofibrils appear to be flexible species as evidenced by the
random curvatures they exhibit following adsorption to the mica surface. The
average diameter of protofibrils measured from the same image used for analysis
of the globular species is 4.4 ± 0.4 nm (based on 15 height measurements). This
value is typical of those obtained by similar analyses (based on > 50 individual
measurements each) of protofibrils grown under a variety of conditions which
range from 3.1 ± 0.2 nm to 4.4 ± 0.6 nm (see for example Chapter 3, Figure 3.4).
This -30% variability in average height measurements from different images is
typical even when the same type of probe and similar setpoints are used for
imaging (which should result in similar tapping forces) and illustrates the
importance of comparing morphologies from within a single scan whenever
possible to ensure the greatest accuracy. Based on the similarity in reported
diameter, the 2-3 nm fibrillar species reported by Stine et al. in Al1-40 (250 pM)
samples after weeks or months in the presence of larger fibrils 8 may be the same
species we describe as protofibrils.
In well resolved scans, some protofibrils show small increases in diameter
at intervals along their axis. Analyzing longitudinal sections (along the fibril
axis) of protofibrils from a typical scan shows that these peaks have an average
spacing of 20 ± 4.7 nm. Due to the nonlinear nature of the protofibril, axial
sections showing more than three repeats are difficult to obtain so averages
included measurements from multiple protofibrils. Individual values for peak to
peak distances show considerable variation with values observed ranging from
13 - 31 nm among protofibrils in a single scan, but values obtained on the same
protofibril are typically more consistent.
The number of AP molecules required to form a protofibril is uncertain
from AFM analysis. Slowly sedimenting "soluble aggregates" (which may
represent A3 in protofibrillar form) of AB1-40 and A31-42 have estimated masses
of ~1,000 kDa (from analytical ultracentrifugation),23 and protofibrils elute in the
void volume of columns with exclusion limits (for dextrans) of -100 kDa.25
Rough estimation for the number of AP's (~4 kDa each) in protofibrils based on
these observations would suggest that there may be between 25 and 250
molecules of AB in protofibrils of varying sizes. Mass-per-length analysis
performed using scanning transmission EM for amylin fibrils may also provide a
useful comparison.29 Amylin (also ~4 kDa) fibrils and A fibrils appear to share
common secondary structures 29,30 and multiple filament wound morphologies
(Goldsbury et al.29 and below). Goldsbury et al. found that 2-5 filaments
(referred to as protofibrils) were wound in a left handed helical sense to form
typical amylin fibrils.29 Each filament had an apparent mass-per-unit length of
-10 kDa/nm (between 2-3 amylin molecules/nm).2 9 If the mass-per-length for
A protofibrils is similar, then there would be 200-300 Ap's in a 100 nm
protofibril.
Type 1 fibrils
Type 1 fibrils are generally the earliest fibril type to appear during A3
fibril formation. A well resolved image of type 1 fibrils (seeded A31-40 sample at
37'C, t = 1 day--for a complete discussion of seeding behavior see Chapter 4) is
shown in Figure 2.7 along with axial and cross sections showing the very regular
periodicity of the diameter increases and a representative diameter measurement
at one of the peaks. The modulation in diameter has an average period of 43 ±
5.0 nm (range = 35.4-51.5 nm) that appears to be the result of a left handed helical
twist of two or more filament subunits. Apparent helicity could arise due to tip
induced artifacts, but results presented in Chapter 4 rule out this possibility. The
winding of two or more protofibril filament subunits to form these fibrils is also
suggested by the diameter of the type 1 fibril (7.8 ± 0.45 nm, range = range 6.4-9.5
nm) measured at the peaks of the periods. This is roughly twice the diameter of
protofibrils (measured from a separate scan). To confirm this relationship of the
relative height for protofibrils and type 1 fibrils, the average heights were
determined for both morphologies from a well resolved scan where they
appeared side by side (not shown). Peak diameters for type 1 fibrils in the scan
were 8.5 ± 0.9 nm (range = 6.8-10.0 nm) compared to an average protofibril
diameter of 4.1 ± 0.6 nm (range = 3.4-5.1 nm). Therefore, the average diameter of
protofibrils appears to be about 48% of the average type 1 fibril diameter.
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Figure 2.7 Representative image and sections of Apl-40 type 1 fibrils. Red and
green arrowheads in the 1 pm square image correspond to the similarly marked
features in the sections shown at right. TOP RIGHT: An axial section of a type 1
fibril showing 426 nm total distance between arrowheads indicating ten periods in
the axial substructure. BOTTOM RIGHT: A cross section of type 1 fibril indicating
the 8.0 nm measured diameter of this representative feature.
Alzheimer's disease senile plaque amyloid fibrils (presumably AP fibrils)
with 8-10 nm diameter, and two filament wound morphology (30-50 n m
periodicity) have been observed in previous EM studies of tissue sections3 1 and
purified plaque material. 3 2,33 This fibril morphology has also been reported
previously for A31-40 fibrils formed from synthetic peptide in vitro.3 4 -36 These
reports support the hypothesis that the type-1 fibril morphology is an important
product of AP fibril formation in vivo and that in vitro systems which produce
this morphology are likely to be useful models for the AD pathogenic process.
Furthermore, amyloid fibrils formed by other proteins including transthyretin,37-
39 calcitonin,4 0 and amylin,29 each have been reported to form fibrils containing
two or more helically wound filaments suggesting that our observations may
also have implications for the general mechanism of amyloid formation (model
discussed below).
Type 2 fibrils
Another fibril morphology, the type 2 fibril, commonly appears along
with type 1 fibrils at time points following the disappearance of protofibrils.
Although they lack the regular height increases which characterize both
protofibrils and type 1 fibrils, they do show less regular discontinuities along
their axis (Figure 2.8, blue arrow). The interval between these dislocations
commonly measured between 100-200 nm, with the intervals along a single fibril
typically varying over a smaller range (± -20nm). The average diameter of type
two fibrils is 4.5 ± 0.4 nm and appears to be very similar to the diameter of
protofibrils. For a better comparison, the average diameter of type 1 and type 2
fibrils was measured from another scan where they appeared together on the
same specimen (not shown). The average diameters were 9.0 ± 0.3 nm for type 1
fibrils (based on 15 measurements, range = 8.3-9.4 nm) and 4.4 + 0.2 nm for type 2
fibrils (range 3.9-4.8 nm). Thus, the diameter of type 2 fibrils is roughly 49% of
the type 1 fibril diameter. The protofibril has a very similar relative diameter
(48%) compared to type 1 fibrils, suggesting that type 2 fibrils may be formed by
simple end to end ligation of protofibrils. However several observations indicate
that this is probably not the case.
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RIGHT: A cross section of type 2 fibril indicating the 4.5 nm measured diameter0 250 500 750The protofibril has avery similar relative d amet r (48) com pared toFigure 2.8 Representative image and sections of A1-40 type 2 fibrils. Red,
green, and blue arrowheads in the 1 .25m square image correspond to the
similarly marked features in the sections shown at right. TOP RIGHT: An axial
section of a type 2 fibril showing both the decrease in diameter that is typical at
the characteristic dislocations (blueocation and an increase in diameter that
is an occasional feature in some type 2 fibrils (red arrowhead). BOTTOM
RIGHT: A cross section of type 2 fibril indicating the 4.5 nm measured diameter
of this representative feature.
The protofibril has a very similar relative diameter (48%) compared to
type 1 fibrils, and so formation of type 2 fibrils by simple end-to-end annealing of
protofibrils cannot be ruled out.25 However, this mechanism seems unlikely
since achieving the proper orientation and proximity necessary for a productive
collision should be a very rare event. Furthermore, the occasional observance
of a height increase rather than a dislocation at an expected interval (red arrow,
Figure 2.8) suggests that this species may also be a multi-filament species but
with a larger winding pitch than the type 1 fibril. The dislocations observed may
represent breaks or tears in a ribbon-like structure caused by the adsorption
process. Therefore the measured height of this feature of type 2 fibrils may
underrepresent their maximal diameter which may lie in the plane of the
substrate. However, we have not observed grooves along the axis or
reproducible differences in width that could confirm the multi-filament nature of
the type 2 fibril. This may be due to significant variability in resolving power
and apparent widths that result from normal variability of tip radius (5-10 nm or
more) for the silicon probes used for these studies. The use of carbon nanotube
probes (which significantly improve resolution) should allow us to determine
whether these features are truly multi-filament species. 26 Narrow ribbon-like
fibrils with a periodicity of ~150 nm clearly made from multiple filaments have
been described as products of A31-42 aggregation in vitro .41 Interestingly, these
fibrils were termed 'mature fibrils' to indicate their prevalence after long
aggregation times. 41 Other species were also described at earlier aggregation
times including globular structures and more granular 'immature fibrils' which
disappeared with time in favor of the mature fibrils.41 These results are
qualitatively very similar to our own.
Other fibril morphologies are observed.
Although type 1 and type 2 fibrils are the predominant fibril
morphologies, fibrillar species which do not fit into these categories are also
observed in some specimens(not shown). Generally, the diameters of these
fibrils are similar to or slightly larger (diameter ~10-12 nm) than the two fibril
types described above. These may represent fibrils formed from different
numbers of filaments (as suggested by previous observations of mutiple higher
order assemblies of filaments in calcitonin 40 and amylin filaments29) or alternate
lateral association modes of similar numbers of filaments (similar to the
polymorphism of flagella which has also been proposed to be the result of subtle
switching in flagellin subunit packing42). It should also be noted that at late time
points fibrils become increasingly difficult to observe in isolation on the
substrate. This appears to be related to the incorporation of fibrils into large
disordered clumps with increasing time and aggitation.
Figure 2.9 A31-40 Aggregate morphologies on HOPG. Images are 2 gim
square.
Morphologies on a different substrate are similar
Only the species that adsorb to the substrate are observed so it is
impossible to rule out the existence of other species that might be very poorly
adsorbed. In order to test the possibility that selective adsorption may bias our
observations, we have performed initial experiments using sample preparation
on freshly cleaved highly ordered pyrolytic graphite (HOPG) surfaces to look for
different species that may adsorb to this hydrophobic surface which do not
adhere to the hydrophilic surface of mica. There was occasionally an apparent
increase in the observation of large spherical species on this substrate (heights 25-
40 nm, the hydrophobic surface HOPG is more prone to contamination so these
could also represent non-A3 derived species) but no additional Af1-40 derived
species were detected (Figure 2.9). The morphology of the protofibrils and type 1
fibrils observed on HOPG was indistinguishable from the observations made on
mica, but type 2 fibrils were not observed.
AP1-42 and AI1-40 aggregate morphologies have similar dimensions
The Apl-42-derived species were very similar to the analogous Apl-40
species with respect to their measured diameter (not shown). The Apl-42
protofibrils had a diameter of 4.2 + 0.58 nm and a periodicity of 22 + 3.1 nm.
Like A31-40, two types of fibrils were detected: periodic type 1 fibrils (diameter
= 7.3 + 0.53 nm, ca. 43 nm period) and type 2 fibrils (diameter = 3.8 + 0.43 nm,
period of dislocations ranged between 100-200 nm).
Physical separation of aggregate morphologies
Filtration
Filtration of A3 solutions/suspensions through 0.2 gm filters has been
commonly employed as a method for separating fibrillar A from "soluble" A3.
An Apl-40 solution (50 jiM) containing a mixture of protofibrils was partially
filtered through a 0.2 gm filter, and aliquots of the filtrate and retentate were
used to prepare specimens on mica for AFM analysis (Figure 2.10). The retentate
was observed to contain a mixture of protofibrils and fibrils, while only
protofibrils and smaller features were observed in the filtrate. Although the
presence of a small amount of fibrillar material in the filtrate cannot be ruled out,
filtration appears to be a suitable method for qualitative removal of enough
fibrillar seed from AP solutions so that a lag phase prior to fibril formation can be
observed (since protofibrils do not seed fibril formation--Chap 4).
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Figure 2.10 Filtration and low speed sedimentation of an Af1-40 solution
containing protofibrils and fibrils. Images are 5 gm square.
Sedimentation
The same solution used in the filtration experiment described in the
previous section was centrifuged for 15 minutes at ~17,000 g in a standard
benchtop microfuge. The resulting separation is qualitatively similar to that
achieved by filtration (0.2 ptm) with Al1-40 protofibrils and fibrils observed in
the pellet while protofibrils and other smaller AP species remain in the
supernatant (occasional fibrils are observed, Figure 2.10). The presence of
aggregated forms of AB in the supernatant demonstrates that the use of similar
procedures to separate "soluble" and "insoluble" A3 would include the amount
of AB in protofibrillar form as soluble AP and may significantly overestimate the
amount of soluble A3 in a solution if protofibrils are present. Sedimentation at
100,000 g for 1 hour does selectively sediment longer protofibrils, but the small
~4 nm globular protofibrils are numerous in the supernatant along with
occasional protofibrils as long as ~50 nm (Figure 2.11). The A3 in the
supernatant is competent to go on to form protofibrils and fibrils (data not
shown).
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Figure 2.11 Sedimentation of protofibrils at 100,000 x g for 1 hour. Images are
1 p~m square.
Preliminary equilibrium density ultracentrifugation experiments have also
been done. Samples of Apl-40 (~25 gg Apl-40 in each, [Apl-40] in solutions
used was 40-45 jiM) in varying stages of fibril formation were adjusted to 40%
sucrose, transferred to the bottom of a centrifuge tube, and overlaid with a 5-30%
linear sucrose gradient. After equilibrilum sedimentation in an ultracentrifuge,
the tubes were fractionated and analyzed by SDS-PAGE/western blot analysis.
AFM analysis of the aggregation state of each sample and the corresponding
sedimentation profile are shown in Figure 2.12. Samples containing pre-fibrillar
aggregates and monomeric AP (aggregation time = 4 h and 24 h) showed similar
patterns with significant amounts of AB migrating into lower density fractions.
A sample containing a mixture of protofibrils and fibrils showed a slight
shift in the distribution toward higher density fractions. No detectable amounts
of AP in the sample containing fibrils alone migrated out of the highest density
fraction. These results show that pre-fibrillar forms of AD have lower densities
compared to fibrillar AD. However, we can not be certain that A protofibrils are
included in these lower density species since the presence of sucrose prevented
the preparation of suitable specimens for AFM analysis of the species present.
Significant separation of pre-fibrillar and fibrillar Al1-40 was not achieved in
these preliminary experiments, but may be possible with modifications in the
sedimentation conditions used.
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Figure 2.12 Equilibrium density ultracentrifugation of Af1-40 aggregates.
AFM images of aggregates present are shown (left) and western blots (right,
arrowheads indicate position of the 4 kDa Af1-40 monomer) showing the
distribution of AP with density. Density is lowest in fraction 1 and increases
linearly to maximum density in fraction 12.
t = 24 h
t = 4 h
Time course for the formation of protein secondary structure
To follow the time course for the formation of secondary structure in an
unseeded solution with time by CD, it was first necessary to obtain a solution of
A01-40 that was as free of seed as possible without using DMSO (the strong
absorbance of DMSO prevents CD analysis). Lyophilized peptide (HCl salt) was
suspended in water and filtered through a 0.2 jM microspin filter to remove any
undissolved fibrillar material and concentrated buffer was added to the filtrate
(an aliquot of the supernatant) yielding a solution containing 50 jiM Al1-40 in 5
mM phosphate, 100 mM NaF, pH 7.3. This solution was incubated at room
temperature and the morphology and secondary structure of aggregates formed
was monitored simultaneously by AFM and CD (Figure 2.13).
Immediately following dilution, rare short fibrils (lengths 500 nm - 1 tm,
about 1 per 100 jim 2) were observed among small globular features by AFM
while the CD curve obtained showed little indication of the presence of ordered
structure. After 2 days numerous protofibrils and occasional fibrils (lengths ~ 1
tm) were observed by AFM in the presence of abundant spherical features in all
size ranges, but there was little change from the original CD spectrum despite the
observation by AFM of what appeared to be a significant population of
structured aggregates. At three days changes in the CD spectrum indicated that
detectable amounts of secondary structure were beginning to form. However,
the CD curve still appeared to indicate the presence of a large proportion of non-
n-sheet structure even though fibrils appeared to be numerous at this point
among a decreasing number of protofibrils and small spherical species. Only
when protofibrils and smaller features had almost completely disappeared in
favor of fibrils at day six did the CD spectrum indicate the formation of
predominantly beta sheet structure in the A01-40 solution. Estimates of the
percent of AP in -sheet and random coil configurations at 0, 3 and 6 days were
made using the Lincomb program43 and are shown in Figure 2.13 (bottom right).
Similar results were obtained for solutions prepared in the same way using
peptides from different sources and when seed material was removed by
sedimentation (100,000 x g, 1 hour) rather than filtration (data not shown).
The delay between the observance of protofibrils and early fibrils and the
appearance of a characteristic -sheet CD curve is consistent with at least two
interpretations-- 1) protofibrils do not have significant 1-sheet structure, or 2)
protofibrils do have significant secondary structural elements but only represent
a small fraction of the total AD in the sample at any time during fibril formation.
Independent evidence from other studies supports the latter interpretation.
Analysis of aggregating solutions of A01-40 by Walsh et al. using size exclusion
chromatography has also observed the transient formation of protofibrils
(represented by the appearance of a peak in the void volume of the column). In
these studies the relative amount of AB1-40 in the protofibril fraction (measured
by relative UV intensity of peaks, recovery of 12 5I-AP1-40 tracer, or
radioimmunoassay) does accumulate to a significant amount but never appears
to represent a majority of AP in the samples.25 Furthermore, CD analysis of
protofibrils obtained in the size exclusion fraction that have been separated from
unpolymerized forms of AP produce spectra that are consistent with a protofibril
structure containing a high percentage of 1-sheet (Dominic Walsh, personal
communication).
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Figure 2.13 Parallel observations of aggregate morphologies and secondary
structure formation during A01-40 fibril formation. TOP: AFM images of
representative 1 pm square regions at the indicated time points. BOTTOM:
CD spectra of the same sample at the indicated time points (left), and estimates
of the amount of 1-sheet and random coil as a function of time (right).
A potential role for the protofibril as a fibril assembly intermediate.
A scenario in which Ap protofibrils are intermediates in the assembly of
the AP amyloid fibril (Figure 2.14) is supported by the fact that the
disappearance of protofibrils occurs over a short time period compared to
protofibril elongation and is concurrent with the appearance of fibrils. Several
additional observations are pertinent to discussions of the probable mechanism.
First, protofibril elongation is much slower than fibril elongation. The scarcity of
small fibrils suggests that once fibrils are nucleated, their growth is rapid and
favorable.1,2 Second, AP type 1 fibrils (formed by both A01-40 and A 1-42) have
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a maximum diameter that is roughly twice the diameter of the AP protofibrils
and appear to be helically twisted. The increased diameter precludes a simple
end-to-end protofibril association mechanism and the apparent helicity suggests
a lateral association and winding of protofibrils during fibril growth. Third, the
significant lag period during which protofibrils grow in length and number in
unseeded AP solutions before fibrils appear suggests that a minimum number
concentration of protofibrils or minimum inter-protofibril overlap may be
required for the nucleation and/or growth of fibrils. Finally, an otherwise
identical solution of A1-40 (45 pM) which was not agitated for eight weeks
(solutions followed for the time course were aggitated prior to sampling)
contained only protofibrils, suggesting that an enhanced frequency of protofibril-
protofibril encounters in agitated solutions promotes fibril formation. Thus, two
or more protofibril or filament subunits appear to associate laterally and twist
helically to form AP type 1 fibrils.
Amyloid fibril formation from subunit filament precursors has been
suggested at least as early as 1974 by Glenner and coworkers 44 based on the
occasional observation of single filament extensions from the ends of multi-
filament murine senile amyloid fibrils by negative-stain EM. More recently,
morphological observations of fibrils formed by human calcitonin 40 and human
amylin 29 have led to models for amyloid fibril formation closely resembling our
own. Finally, Walsh et al. have also proposed a similar protofibril assembly
model based on independent observations of the initial stages of AB fibril
formation as described above.25
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Figure 2.14 Possible AP fibril assembly pathways.
Although the direct precursor mechanism is attractive, we have not ruled
out the possibility that protofibrils are rapidly formed, but are in fast equilibrium
with monomeric AP, which slowly assembles into the more stable type 1 and
type 2 fibrils (Figure 2.14). In either scenario, the stabilization of protofibrils
would inhibit fibril formation, either by blocking protofibril-protofibril
interactions or by slowing the protofibril-monomer equilibrium. In addition, the
relative stabilities of the multiple fibrillar morphologies cannot be determined
from these experiments. It must be emphasized that species which do not
adsorb onto mica are not seen by this method. However, preliminary
experiments using a hydrophobic graphite surface (HOPG) show the same
species and no additional ones. In addition, since the velocities of the individual
steps may have different concentration-dependencies, it is conceivable that the
lifetimes of these species may be altered at lower or higher concentrations of AP
or that new species become apparent. The protofibril-to-fibril transition seems to
be the best candidate for the nucleation-dependent step, since protofibrils
apparently must reach a certain length and/or concentration before rapid fibril
growth occurs. Growth of the fibrils, once nucleated, appears to have a first
order dependence on the concentration of AB.12,4 5
Although there is no direct evidence presently available for the transient
existence of AP protofibrils in vivo, an apparently non-fibrillar form of deposited
AP, termed diffuse amyloid plaque, is prevalent in individuals known to be
predisposed to AD, leading to the proposal that it represents an innocuous
precursor to neuritic amyloid. 46 Diffuse plaque may contain protofibrillar AP,
not easily detected by electron microscopy. It will be important to study this
material by AFM in the future. Significantly, AP protofibrils, like diffuse
amyloid plaques, are more difficult to sediment than amyloid fibrils. The work
described in the remaining two chapters of this thesis describe our efforts to
provide a more detailed characterization of the process of protofibril formation
(Chapter 3) and clarification of the role of the protofibril in A3 amyloid fibril
growth. We hope that the additional information gained will help provide the
foundation necessary to address the possible relevance of the protofibril to the in
vivo disease process.
Experimental
Materials
Synthetic Apl-40 (TFA salt, used in time course and morphology examinations)
was purchased from Quality Controlled Biochemicals Inc. (Hopkinton, MA).
Synthetic Al1-42 (TFA salt) and Apl-40 (HC1 salt, used in CD/AFM study) was
provided by Dr. David Teplow of the Center for Neurologic Diseases.
In vitro fibril formation
AFM experiments. Stock solutions of Ap1-40 and Ap1-42 were made by
dissolving each peptide in DMSO at 0.34 (Aj1-42) or 0.84 mM (Af1-40) and, in
the case of A01-40, filtering through Millex-FG 0.22 grm filters (Millipore), or 0.2
jtm microspin filtration units (Whatman). Final concentrations of the DMSO
stocks were determined by quantitative amino acid analysis. Aliquots of the
DMSO stock solutions (9 nmol in ca. 11 jiL for A31-40, 4 nmol in ca. 11 jgL for
AP1-42) were added to aqueous buffer (200 jiL total volume, 100 mM NaC1, 10
mM NaH2PO4, pH 7.4) and immediately vortexed to mix before allowing fibril
formation to proceed at room temperature.
CD/AFM time course experiments. Lyophilized Ap1-40 (HC1 salt) was suspended
in water, sonicated to dissolve the peptide, and filtered through a 0.02 M
syringe filter to remove any undissolved fibrillar material. Concentrated buffer
was added to the filtrate (an aliquot of the supernatant) yielding a solution
containing 50 jgM Apl-40 (in 5 mM phosphate, 100 mM NaF, pH 7.3). This
solution was incubated at room temperature and the morphology and secondary
structure of aggregates formed was monitored simultaneously by AFM and CD.
Atomic Force Microscopy
Speciman preparation. At the indicated time points, the aggregation mixtures were
mixed by gentle tapping and samples were prepared for imaging by transferring
5 jL of the suspension to the surface of freshly cleaved mica. After 1 min. the
substrate was rinsed twice with 50 jgL water to remove salt and loosely bound
peptide. Excess water was removed with a gentle stream of filtered compressed
air and the sample was imaged immediately.
AFM operation. All images were obtained in ambient conditions in tapping mode
using a Nanoscope IIIa force microscope (Digital Instruments, Santa Barbara,
CA) operating in TappingModeTM with an etched silicon Nano ProbeTM (model
TESP: 125 mrn cantilever, spring constant = 20-100 N/m, tip radius = 5 - 10 nm, or
model FESP: 125 gim cantilever, spring constant = 1-5 N/m, tip radius = 5= 10
nm). Scanning parameters varied with individual tips and samples, but typical
ranges were as follows: 1) TESP--starting RMS amplitude, 2.0-2.5 V; setpoint, 1.5 -
1.75 V; resonant frequency, 250-350 kHz; scan rate, 0.5-2 Hz. 2) FESP--starting
RMS amplitude, 1.4-2.0 V; setpoint, 1.0-1.6 V; resonant frequency, 60-80 kHz;
scan rate, 0.8-2 Hz.
Measurements. The diameters of features as described herein were obtained by
averaging 2 30 peak height values obtained for the stated morphology using
nanoscope section analysis software (+ standard deviation). Periodicities were
determined by averaging 30 peak-to-peak distances (± standard deviation)
except for the case of the A01-42 type 1 fibril, where only 12 values were
available.
Separation studies
Filtration. To a 0.2 jtm nylon microspin filter unit (Whatman) was added 100 itL
of an Apl-40 solution containing protofibrils and fibrils. The filter unit was spun
for ~15 seconds @ 4,000 rpm in an Eppendorf model 5415C benchtop
microcentrifuge with a fixed angle rotor. Aliquots (4jtL) were removed from the
filtrate and retentate and used to prepare specimens for AFM analysis as
described above.
Low speed sedimentation. To a microcentrifuge tube was added 100 gL of an A01-
40 solution containing protofibrils and fibrils. The sample was centrifuged for 15
minutes at maximum speed (14,000 rpm, ~17,000 x g) in an Eppendorf model
5415C benchtop microcentrifuge with a fixed angle rotor. To examine the
material in the supernatant, 4 jtL aliquot was carefully taken from the top 1/3 of
the sample and used to prepare a specimen on mica for AFM analysis as
described above. Since no visible pellet was generated in the sample, the
sedimented material (pellet material in images) was analyzed after making the
supernatent specimen by careful removal of an additional 4jtL aliquot bottom of
the tube and preparing a specimen on mica for AFM analysis as described above.
High speed sedimentation. An aliquot (200 L) from an Apl-40 solution containing
only pre-fibrillar A1l-40 aggregates (assessed by AFM prior to use) was
centrifuged for 1 hour at 50,000 rpm in a Beckman TL-100 ultracentrifuge with a
model 100.2 fixed angle rotor (-100,000 x g). 180 gL of the supernatant was
removed and an aliquot of this was used to prepare a specimen for AFM
analysis. The remaining ~20 gL of the sample containing the pellet was
reconstituted to 200 pL total volume with buffer (10 mM phosphate, 100 mM
NaC1, pH 7.4). The pellet was gently homogenized by drawing the sample
repeatedly through a pipette, and an aliquot of this suspension (4 jtL) was used
to prepare a specimen on mica for AFM analysis.
Equilibrium density ultracentrifugation. Aliquots of A31-40 samples containing
mixtures of morphologies as described in the text (-25 gg total peptide in each
sample) were adjusted to 40% sucrose (4 mL total volume) and transferred to the
bottom of a 13 mL ultracentrifuge tube. The sample was overlaid with a 5-30%
linear sucrose gradient (8 mL) and centrifuged for 20 hours at 39,000 rpm in a
Beckman L8-55M ultracentrifuge with a SW 41 rotor. One mL fractions were
collected from the top and 10 gL aliquots from these fractions were boiled in
Laemmli sample buffer for 5 minutes, separated using a 10-20% polyacrylamide
tris-tricine gradient gel (Novex mini-gel), and transferred to a nitrocellulose
membrane (pore size of 0.22 tm, Schleicher and Schuell). The membrane was
blocked with 5% non-fat dry milk in TBST (10 mM Tris, pH 7.4, 150 mM NaC1,
0.05% Tween-20) for 1 hour at room temp, probed with anti-A mouse
monoclonal 2G3 in TBST containing 1% bovine serum albumin for 1 hour at
room temp, washed, and incubated with goat anti-mouse IgG conjugated to
horseradish peroxidase. Bound antibodies were visualized by chemiluminescent
substrate as described by the manufacturer (NEN life science products).
Circular Dichroism
CD spectra were obtained using an AVIV model 62A DS
spectrophotometer. The sample was scanned four times at 23°C in a quartz cell
(0.1 cm pathlength) at 1 nm intervals over the wavelength range 198-240 nm.
Buffer and cell backgrounds were subtracted from each spectrum. Results are
expressed in units of deg cm2 dmol-1. The percent of B-sheet and random coil
structures present was estimated with the Lincomb program 43 using spectra fit
to the basis spectra set of Yang et al. 47
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Chapter 3
AFM Measurements of A 1-40 Protofibril Growth
In the previous chapter, AFM experiments were described which
identified and characterized several distinct aggregate species which form
during fibril formation by synthetic Al1-40 and Al1-42 in vitro. The first-
detected species was not the amyloid fibril as predicted by the simplest
interpretaion of the nucleation dependent polymerization mechanism.
Instead, a number of smaller oligomeric AP assemblies including the AP
protofibril were observed for extended periods prior to the formation of
prototypical amyloid fibrils by both peptides. Since very little was known
about the behavior of these pre-fibrillar species and the events preceding the
onset of fibril formation, we decided to more closely examine the time course
of AP protofibril formation. For these initial studies we chose to use Al1-40
instead of A31-42 since its slower onset of fibril formation allows greater
opportunity to observe protofibril formation and growth.
This chapter describes our efforts to develop an AFM-based method for
comparing protofibril growth under a variety of conditions. Changes in the
measured lengths of protofibrils with time are used as the basis for comparing
the rate of of protofibril formation. After briefly discussing the basic features
of the detection methods used and a series of experiments designed to test the
reproducibility of the measurements, this chapter will present data that
indicates that protofibril formation increases with time, Al31-40
concentration, temperature, and ionic strength. These observations expand
the range of conditions where protofibril formation is observed and indicate
the usefulness of AFM as a tool for comparing protofibril growth.
AFM-based methods for monitoring protofibril growth
Although AFM examination cannot provide quantitative information
about changes in the amount of protofibrils with time, it can very accurately
measure the dimensions of individual protofibrils in a specimen. We
believed that measurements of protofibril length could provide the basis for
quantitative comparisons of protofibril growth since the qualitative
observations from the time course of fibril formation discussed in Chapter 2
suggest that protofibril lengths, like the amount of protofibrils, 1 increase with
time during protofibril formation. Two methods used to compare the lengths
of protofibrils among different specimens are described below.
Measuring average protofibril length
For determinations of the average protofibril length, regions
containing > 50 protofibrils were selected from suitable specimens (see below)
and the lengths of all protofibrils in that region were measured and used to
calculate the average. The -4 nm globular species present in the scan were
included in the length average as protofibrils with lengths 4.5 nm
(approximately equal to their diameter). Error in the average length
measurements is estimated to be ± 5 nm. The error is difficult to determine
empirically, but the digital nature of the image data, and imprecision when
approximating the curvature of the protofibrils will contribute to
measurement error. Variation in specimen preparation conditions needed to
optimize protofibril density could also influence the value of protofibril
length and were controlled for experimentally (results discussed below).
While using the average protofibril length to represent changes in
protofibril growth with time provides a good way to compare changes in the
protofibril population as a whole, it may provide deceptive information if
used to estimate elongation rates for protofibrils. Increases in average
protofibril length only provide an accurate representation of the protofibril
elongation rates if the number of protofibrils remains constant during the
measurement period. If new (shorter) protofibrils form between
measurements then the growth rate would be underestimated by the increase
in average length.
Measuring the length of the longest protofibril observed
By extension of the same argument, the longest protofibrils should
have formed closest to t = 0 and continued to grow during the period prior to
sampling. Therefore, the length of the longest protofibril in a specimen could
provide an estimate of elongation rate which might more closely represent
the actual elongation rate for protofibrils. This method will be used to
provide an alternate estimate for the average growth rate in Al31-40 samples.
To obtain this value we take the same scan containing the region used for
average length measurements, divide it into quadrants and then find and
measure the longest protofibril present in each quadrant. We then use the
average of these lengths + the standard deviation of the values to represent
the length of the longest protofibril. We use this averaging method instead of
relying on the length of a single protofibril to improve confidence that the
value obtained is an accurate representation of the longest protofibrils present
and to provide some sense of the variability of this measurement. The
elongation rate is obtained by dividing this length by the time elapsed prior to
sampling. It is important to realize that elongation rates measured this way
(and estimates based on the longest protofibril method) represent average
elongation rates, and could significantly underestimate actual elongation
rates if protofibrils are prone to disassembly episodes during growth (as is the
case for microtubules) 2,3 or a population of protofibrils becomes dormant
while other protofibrils in the sample continue to grow (a similar scenario
has been described for in vitro elongation of salmonella flagella).4
Effects of specimen preparation conditions on measurements
To reliably determine the lengths of protofibrils in a specimen required
that the protofibrils be evenly dispersed on the mica substrate so that
individual protofibrils could be distinguished and measured. Alterations in
the incubation time on mica and the A31-40 concentration in the aliquot
applied to the substrate can be used to achieve protofibril adsorption densities
from most samples that allow accurate length determinations. Reducing
incubation times for undiluted aliquots on mica from 1 min (used in time
course experiments in Chapter 2) to 30 seconds generally produced suitable
specimens from solutions with A31-40 concentrations 40 gM. Solutions
with Apl-40 concentrations > 40 RM required brief dilution of aliquots to
concentrations 40 gM before specimen preparation to produce suitable
specimens for length measurements (example images shown in figure 3.1)
Because it was possible that these alterations to the specimen preparation
procedure could change the lengths of protofibrils which adsorb to the mica
surface, their effects on protofibril length measurements were investigated to
test the reproducibility and accuracy of length measurements made using this
method.
Controlling for the effect of brief dilution.
After 7 days and 22 days of incubation at room temperature (average
temperature = 180C), aliquots of an Apl-40 solution (32 jiM) were used to
make specimens either without dilution or following brief ( 30 seconds)
dilution to 16 jM. Representative images of these specimens are shown in
Figure 3.1 and the average protofibril length and the length of the longest
protofibril was determined for each sample and the results are summarized
in Table 3.1.
32 gM A 01-40, Diluted to 16 gM
Figure 3.1 Typical protofibril distributions used for measuring protofibril
lengths. Both specimens were prepared from the same suspension of Apl-40
protofibrils that had been growing for 22 days at room temperature (18 0 C).
Images are 1 jim square.
Table 3.1 Protofibril lengths measured with and without dilution. After 7
days and 22 days of incubation at room temperature, aliquots of an Al1-40
solution (32 gM) were used to make specimens either without dilution or
following brief (< 30 seconds) dilution to 16 gM.
Incubation time Dilution Average Length Longest Protofibril
prior to analysis
7 days no 24.4 ± 5 nm 130 + 10 nm
yes 23.6 ± 5 nm 121 + 7 nm
22 days no 29.4 + 5 nm 136 + 16 nm
yes 34.5 + 5 nm 157 + 49 nm
I
32 M AP1-40, Undiluted
For both time points, the average protofibril length and longest
protofibril length for specimens prepared either with or without dilution
were within the error of the measurements. Although it is not possible to
test the effect of dilution in this way for dilution from higher Apl-40
concentrations (since the protofibril density is too great for accurate length
measurements in undiluted samples above ~40 gM), these results suggest
that dilution of protofibrils briefly (less than 30 seconds in all cases) prior to
measurement does not significantly alter the lengths of protofibrils observed
using this method.
The effect of extended dilution.
A solution of Al1-40 (160 gM) was diluted to 8 gM after aggregation at
180 C for 4 hours and imaged immediately, 25 minutes, 3 days, and 7 days
following dilution (Figure 3.2).
Figure 3.2 Images of protofibrils following dilution. After 4 hours of
incubation at 180C an A1l-40 (160 [M) solution was diluted to 8 jM and
imaged at the indicated times following dilution. Images are 1 gm square.
The values for the average protofibril length and longest protofibril
measurements at each time point are shown in Table 3.2. No significant
change in the average protofibril length or the average length of the longest
protofibril was observed during the first 25 minutes of dilution. Dilution for
3 days did result in significant reductions in both length measurements and
also appeared to reduce the overall amount of protofibrils adsorbed to the
mica surface. After 7 days, protofibrils numbers were reduced even further,
but the additional decreases observed for the average length and longest
protofibril measurements were within the error of the measurements. The
reduction in the length and number of protofibrils during extended dilution
may reflect protofibril disassembly caused by dilution. However, the change
is too slow to cause protofibril lengths to be significantly underestimated in
these experiments where the dilution prior to specimen preparation and
AFM analysis never exceeds 1 minute.
Table 3.2 Effect of extended dilution on protofibril lengths. An AP1-40
solution (160 M, t = 4 hours) containing protofibrils was diluted to 8 pM and
protofibril lengths were analyzed at the indicated times following dilution.
Dilution time t = 0 25 min 3 days 7 days
Average 30.6 + 5 nm 30.5 ± 5 nm 17.0 + 5 nm 14.0 ± 5 nm
Length
Longest 177 ± 21 nm 193 + 34 nm 106 + 24 nm 86 ± 13 nm
Protofibril
Controlling for the effect of incubation time on the mica substrate.
Aliquots from an AP1-40 protofibril suspension (32 jM briefly diluted
to 16 tM after 7 days at 180 C) were placed on mica for 30 seconds or 1 minute
before rinsing away unbound material and imaging. The average protofibril
length was 23.6 ± 5 nm for the 30 second specimen and 22.2 ± 5 nm for the 1
minute specimen. The longest protofibril measured 122 ± 7 nm in the 30
second specimen, and 110 ± 16 nm in the 1 minute specimen. In another
comparison, 30 second and 2 minute incubations on mica were used to
prepare specimens from a different Ap1-40 solution (200 jM briefly diluted to
to 20 jM after 14 hours at 180 C). The average protofibril length was 45.4 ± 5
nm in the 30 second specimen and 49.8 ± 5 nm in the 2 minute specimen.
From the same images the longest protofibril measured 131 ± 6 nm in the 30
second specimen, and 148 ± 19 nm in the 2 minute specimen. No significant
changes in protofibril length measurements resulted from variations in the
incubation time on mica between 30 seconds and 2 minutes. The incubation
time on mica was kept as constant as possible among specimens that were
used for comparisons of protofibril lengths in the following discussions, but
the actual times may differ by up to 5 seconds. Based on these observations,
such small variations are unlikely to significantly alter the length of
protofibrils observed.
Measurements of protofibril growth
Time-dependent elongation of protofibrils.
Images of specimens prepared from a 100 gtM suspension of AB1-40
after 2 days, 7 days, and 18 days incubation at room temperature are shown in
Figure 3.3. Comparison of protofibril lengths in these images indicated that
protofibrils longer than 100 nm are observed with greater frequency over time
(1% of protofibrils at 2 days, 8% after 7 days and 20% after 18 days) while
protofibrils < 40 nm long remain common (Figure 3.3-Histograms).
The number of protofibrils observed in a 1 gm 2 region started at 440 in
the 2 day specimen, decreased to 256 at 7 days and was 218 after 18 days. The
trend toward decreasing numbers of protofibrils on specimens over time was
a general trend among the specimens described in this chapter with more
rapid decreases generally associated with more rapid protofibril elongation. If
this trend reflects actual differences in protofibril number in solution, it could
be an indication that smaller protofibrils (for example the 4.5 nm globular
species) combine to form longer protofibrils. The average protofibril length
was 22.4 nm at 2 days, increased to 37.5 nm at 7 days and reached 58.8 nm at 18
days (Figure 3.4). A similar trend toward increasing length with time is
observed for the longest protofibrils in solution (Figure 3.4). The average
diameter of the protofibrils does not change significantly with time as the
lengths increase (Figure 3.4) indicating that growth occurs primarily, if not
entirely, by addition of A3 onto the ends of protofibrils.
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Figure 3.3 Images and histograms of protofibril growth. 1 [tm square images
on left and histograms on right showing A31-40 protofibril lengths increasing
with time. Total protofibril numbers in histograms were 110 (in 0.25 [pm 2) at
day 2, 64 (in 0.25 m2') at day 7, and 109 (in 0.50 nm'2) at day 18.
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Figure 3.4 Time course of measured protofibril dimensions. TOP: Average
protofibril lengths (left) and longest protofibrils (right) measured from the
images in Figure 3.3. BOTTOM: Measurements of average protofibril heights
at each time point.
Concentration-dependent elongation of protofibrils.
The elongation of protofibrils was followed in solutions with different
A31-40 concentrations (16 gM, 32 gM, 80 gM and 160 gM) but otherwise
identical incubation conditions. After incubating for 4 hours at room
temperature, only rare protofibrils showing no evidence of elongation were
observed in the 16 [M sample while protofibrils were readily observed at the
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higher concentrations (Figure 3.5). At 2 days and all later time points,
protofibrils were present in all samples (no fibrils observed). Protofibrils from
the 160 CiM sample were less evenly distributed on the substrate, and often
appeared to be closely associated into clumps on the surface. Since the length
of protofibrils in these clumps could not be accurately determined, only the
isolated protofibrils were used for length determination in specimens from
this sample.
The average lengths of the protofibrils in each sample were determined
and plotted as a function of time in Figure 3.5. Average lengths generally
increased with A31-40 concentration, although the differences were within
experimental error in some cases (especially at lower time points). For the 160
gM sample, an initial increase in average length was seen over the course of
the first week, but a significant decrease occured between 7 and 22 days. The
reason for this decrease is not clear, but it could be related to the increased
tendency of the protofibrils in this sample to associate if longer protofibrils are
selectively incorporated into these larger aggregates.
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Figure 3.5 Time course of protofibril growth at different Al1-40
concentrations. TOP: AFM images of protofibrils formed at the indicated
times and Al1-40 concentrations. The 80 p.M and 160 p.M samples were
diluted to 16 gM for specimen preparation, and the 16 RM and 32 RM samples
were used without dilution. All images are 1 pm square. BOTTOM: The
average protofibril length as a function of time for each concentration.
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To obtain estimates of elongation rates based on the average protofibril
length, we used the earliest 4 hour time point and assumed a protofibril
length of 0 nm at t = 0. We then divided the average length of protofibrils for
each concentration by 4 to give the estimated elongation rate in nm/hour (the
errors represent the estimated ± 5 nm error of the average protofibril length
divided by 4). Since protofibrils were not numerous enough to accurately
determine an average length in the 16 jiM sample at 4 hours the calculation
was only made for the three remaining samples and yielded values of 3.0 ± 1.3
nm/h at 32 jRM, 3.5 ± 1.3 nm/h at 80 jiM, and 9.4 ± 1.3 nm/h at 160 jiM. Only
the 160 M sample showed a significant increase in elongation rate using
these methods. These values are plotted as a function of Ap1-40
concentration in Figure 3.6.
The longest protofibril present in these samples at 4 hours was 50 ± 10.6
nm for the 32 jiM sample, 94 ± 7.9 nm for the 80 gM sample and 179 ± 19.2
nm for the 160 jiM sample. These values are much higher than would be
predicted by the estimated elongation rates based on the average protofibril
length, and as discussed previously, may be more accurate representations of
the protofibril elongation rate since they are not biased by the presence of
shorter protofibrils which may may be continuously formed during the
measurement period. Plotting the elongation rate calculated based on these
values as a function of Apl-40 concentration (Figure 3.6) shows a linear (R2 =
0.998) relationship between elongation rate based on the longest protofibril
and the Ap1-40 concentration. The linear dependence of protofibril growth
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rates (based on the longest protofibril measurements) on the initial Apl-40
concentration suggests that protofibril growth does occur by sequential
addition of an AP species.
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Figure 3.6 Concentration dependence of protofibril growth. LEFT:
Elongation rate based on average protofibril length vs. [AP1-40] (R2 = 0.907).
RIGHT: Elongation rate based on longest protofibril in each sample vs. [AP1-
40] (R = 0.998). Data for both graphs is from the four hour time point.
The concentration-dependence of seeded AB aggregate (presumably
fibril) growth in vitro, has been measured by following increases in
thioflavine T fluorescence5 , and incorporation of radiolabeled Apl-40 into
brain-derived 6 and synthetic 7 amyloid. In each of these studies, a linear
relationship was observed between the A31-40 concentration and the rate of
growth leading the authors to propose that seeded fibril growth occurs via
sequential incorporation of monomeric AP to growing fibril ends.5-7 Our
results are consistent with a similar first order mechanism for protofibril
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elongation, but it is not clear whether monomeric A3 is the assembly
substrate. Because multiple distinct small globular species are observed in
these solutions by AFM (which may represent Al1-40 monomer and/or
small oligomers), monitoring growth rate alone without the ability to
measure changes in the quantity of each possible assembly species cannot
establish the identity of the assembly substrate. Although this analysis is not
possible using AFM analysis of protofibril growth, it may be possible with
other techniques including analytical ultracentrifugation analysis which have
the potential to separate and quantitate the species present in aggregating
solutions of A3.
Temperature-dependent elongation of protofibrils.
Protofibril growth was monitored in identical solutions of AB1-40 (100
gM) which were incubated at 30C, room temperature (averaging 180 C), and
37 0 C to probe the effect of temperature on the process. AFM images of these
samples reveal obvious increases in protofibril lengths with increasing
temperature at each time point examined (representative time point shown
in Figure 3.7).
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Figure 3.7 AFM images of Al1-40 protofibrils grown at different
temperatures. Parallel solutions containing 100 pM total Al1-40 were
incubated for 7 days at the temperature indicated. All images are 1 p m
square.
The average length of protofibrils from each of these images is plotted
as a function of time in Figure 3.8. Both the average length at each time point
and the rate of increase of the average length with time were found to depend
on temperature as follows: 37 0C > 180C > 3C. Incubation of protofibrils (40
gM A1l-40, t = 9 days) grown at room temperature for 15 minutes at 30C, or
37°C just prior to specimen preparation did not significantly change the
average protofibril lengths for these samples (38.2 nm for the 4°C specimen,
44.6 nm for the RT specimen, and 39.0 nm for the 37°C specimen). Therefore,
the differences in average length most likely reflect differences in assembly
rate and were not caused by temperature dependent adsorption effects on the
observation of average protofibril length.
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Figure 3.8 Temperature dependence of protofibril average length. LEFT:
Average protofibril length as a function of time for the indicated
temperatures RIGHT: Arrhenius plot of day 2 data showing significant
deviation from linear behavior. R2 = 0.940. [A31-40] = 100 gM for all data
points.
Figure 3.9 shows the lengths of the longest protofibrils found in the
specimens and an Arrhenius plot of the natural log of the average growth
rates based on these values versus the reciprocal of the absolute incubation
temperature (the elongation rate was based on the longest protofibrils in the
specimens after 2 days and calculated as described above except that values
and errors are divided by 2 and represented in units of nm/day). The data
from the previously mentioned control experiment for temperature
dependent effects on protofibril average length was re-examined to test
whether temperature changes just prior to adsorption altered the length of
the longest protofibril observed. The longest protofibril lengths found were;
140 ± 8nm at 30C , 152 ±21 nm at 180C, and 148 ±8 nm at 37°C. As was the case
for average protofibril length, the temperature of the sample at the time it is
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applied to mica does not significantly alter the length of the longest protofibril
observed.
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Figure 3.9 Temperature dependence of protofibril growth based on longest
protofibril method. LEFT: Length of longest protofibril vs. time. RIGHT:
Arrhenius plot based on longest protofibril at t = 2 days for each temp. R' =
0.993
The Arrhenius plot based on the longest protofibril length shows good
linearity over the temperature range examined and is a better fit than that
obtained from the average length data. Although Arrhenius behavior for
protofibril growth in the temperature range we investigated has not been
confirmed by other methods, the improved fit for the longest protofibril
derived rate data provides another indication that measuring average
protofibril lengths provides less reliable rate data. Since we do not know the
number of A3 molecules in a given length of protofibril, the observation of
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Arrhenius behavior does not allow us to make a meaningful estimate of the
activation energy of protofibril growth.
Ionic strength-dependent protofibril growth.
Aggregation of 100 p.M A31-40 at room temperature was followed in
100 mM phosphate buffer (pH 7.4) containing varying amounts of NaCl (no
added NaC1 and 50, 100, or 500 pm added NaC1). Representative images of
these samples are shown in Figure 3.10. For the sample without NaC1, there
was very little evidence of aggregation--protofibrils were observed only
observed at incubation times 2 7 days and then only occasionally (-5
protofibrils per pm 2, lengths 50 nm).
No NaCI 50 mM NaCI 100 mM NaCI 500 mM NaCI
Figure 3.10 Images of protofibrils grown at different [NaC1]. Parallel solutions
containing 100 gM total AP1-40 were incubated for 7 days at the [NaCl]
indicated before specimens were prepared using identical incubation
conditions. All images are 1 pm square.
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Figure 3.11 [NaC1] dependence of average protofibril length. TOP: Average
protofibril length vs time at the indicated [NaCl] (left), and protofibril growth
rate vs. [NaCl] calculated using data from the the first time point examined
(right). BOTTOM: Longest protofibril vs time at the indicated [NaCl] (left),
and protofibril growth rate based on longest protofibril measurements vs
[NaC1] (right).
Protofibrils were common and well dispersed at all time points
examined for the samples containing 50 and 100 mM NaC1. However, at 500
mM [NaC1] protofibrils were observed at early time points to form large
disordered mats. Possibly as a result of this clumping, isolated individual
protofibrils were obseved less frequently with time making it impossible to
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determine length averages by day 18. Where sufficient protofibrils were
observed to determine the average protofibril length and the length of the
longest protofibril posible, the data indicated that average protofibril lengths
increased significantly with NaC1 concentration and time (Figure 3.11).
Growth rates calculated from both sets of data at 2 days also increased
significantly with [NaCl].
Abundant literature precedent exists for ionic strength being of critical
importance for biological specimen adsorption on mica (See for example
Hansma et al.,8 and Muller et al.9 ). As a result, the absence of protofibrils on
the specimens made from samples without added NaCl in the buffer does not
necessarily indicate that protofibrils are not forming in those solutions. To
test whether NaCl concentration influences the length of protofibrils
adsorbed to mica, protofibrils from the same 100 RM Apl-40 solution were
diluted into buffer containing 50, 100, and 500 mM NaCl (final A1l-40 = 25
ptM) for 30 seconds before preparing specimens for AFM analysis. The
average length of protofibrils and the length of the longest protofibril was
determined for each specimen and the results are summarized in table 3.3
below. The NaCl concentration during specimen preparation did not cause
significant differences in the average protofibril length or the length of the
longest protofibril.
111
Table 3.3 The effect of NaCI concentration on protofibril adsorption. Aliquots
containing protofibrils from the same 100 gM A1-40 solution were diluted
into buffer containing 50, 100, and 500 mM NaCl (final A1-40 = 25 gM) for 30
seconds before preparing specimens for AFM analysis of protofibril lengths.
[NaC1] 50 mM 100 mM 500 mM
Average Length 38.4 ± 5 nm 47.4 ± 5 nm 39.2 ± 5 nm
Longest Protofibril 180 ± 50 nm 167 + 32 nm 154 ± 21 nm
Protofibril growth at acidic pH.
We compared the aggregation of 50 gM A31-40 at pH 1.0 (0.1 N HC1,
used previously in dynamic light scattering investigations of fibril growth
kinetics) 10 pH 4.5 (10 mM acetate-buffered saline), pH 5.8 (10 mM MES-
buffered saline), 11 and pH 7.4 (10 mM phosphate-buffered saline) (saline = 137
mM NaCl, 27 mM KC1). Within 5 days following dilution there were visible
differences in the solutions with the solutions at pH 4.5 and 5.8 containing
flocculent precipitate while the at pH 1.0 and pH 7.4 remained clear (similar
observations have also been reported by Wood et al. for pH 5.8 solutions). 11
AFM images of specimens prepared from these samples are shown in Figure
3.12.
The pH 1.0 sample contained long filaments (lengths commonly 2
1itm) that showed little evidence of association/clumping and had
significantly smaller diameters than fibrils formed at pH 7.4 (3-4 nm at pH 1,
compared to 8-9 nm at pH 7.4). In contrast, the samples at pH 4.5 and pH 5.8
both produced specimens characterized by very large masses of material (often
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as large as 5 gm) that displayed features closely resembling protofibrils
extending from their periphery. In all cases the appearance of the aggregates
formed differed significantly from those formed in phosphate buffered saline
at pH 7.4. Because of the rapid formation of very long aggregates at pH 1 and
the association of protofibrils into large masses at pH 4.5 and 5.8, it was not
possible to compare elongation rates using length measurements.
height jm amplitude im height 5 tm height 1 g±m
0.1N HCI, t = 5 days pH 4.5, t = 34 days pH 5.8, t = 5 days pH 7.4, t = 7 days
Figure 3.12 Apl-40 aggregates differ with changing pH.
Previous investigations of A aggregation as a function of pH have
indicated that maximal aggregation in unseeded Al1-40 solutions (as
determined by detection of beta sheet, 12,13 turbidity, 14 Congo red binding,11
and thioflavine T binding5, 11) occurs between pH 5 and pH 6. Wetzel and
coworkers have demonstrated that aggregates formed at pH 5.8 , in contrast to
fibrillar pH 7.4 aggregates, were much more amorphous but sometimes
appeared in electron micrographs as large (widths in the 100 nm range)
bundles of small filaments. 11 Interestingly, according to Wetzel et al., the
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non-fibrillar pH 5.8 aggregate was unable to seed fibril formation at pH 7.4 or
convert to fibrils when the sample was adjusted to pH 7.4.11
SUMMARY
The temporal increases in protofibril lengths reported here are in good
agreement with the time-dependent increase in the amount of protofibrils
observed using size exclusion chromatograpy. 1 In addition to providing
complementary information about the progress of protofibril formation,
AFM analysis provides the ability to directly detect changes in aggregate
morphology that could result from changing aggregation conditions. 11 This
additional capability ensures that comparisons made between protofibril
formation over a variety of conditions are based solely on changes in the
formation of protofibrils and not other assemblies with similar physical
behavior.
We have also observed significant increases in the rate of protofibril
elongation with increasing Al1-40 concentration, temperature, and ionic
strength. These observations increase the range of conditions where
protofibril formation is observed and provide further support for the
involvement of this species in unseeded Apl-40 aggregation in vitro. We
have also observed that the morphology of Apl-40 aggregates depends on the
pH at which they were formed as previously reported. 11
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These AFM analyses do not by themselves provide conclusive
evidence to support detailed interpretations of the molecular mechanism for
protofibril formation and growth. Determination of the molecular events
involved in amyloid formation will require both qualitative demonstration
of the structure and assembly relationship of the various species present
during fibril formation and quantitative understanding of the changing
population of each distinct species present during the formation and growth
of protofibrils and fibrils. The ability of AFM to observe RNA polymerase
activity in real time 15 suggests that it may be possible to obtain useful
information by following the growth of single protofibrils and fibrils on a
substrate in an aqueous environment if current limitations in lateral
resolution and substrate binding in fluid for AP can be overcome. This
analysis could distinguish between steady elongation expected for sequential
incorporation of monomeric A3 and quantized increases in length that
should result from incorporation of discrete oligomeric intermediates.
Recently, we have achieved significant improvements in resolution for AFM
imaging of biological specimens using carbon nanotube tips in collaboration
with Stanislaus Wong and Charles Lieber,16 and progress toward achieving
stable adhesion in fluids is being made in our lab. Analytical
ultracentrifugation methods for analyzing the association state of small
peptides17 have been described which may be able to provide information
about the changing populations of the species we have observed by AFM.
115
Experimental
Protein substrate
Synthetic Ap1-40 was purchased from Quality controlled Biochemicals Inc.
(Hopkinton, MA).
Preparation of seed-free A31-40 stock solutions
Stock solutions of A31-40 in dimethyl sulfoxide (DMSO) were prepared at
concentrations of 12 to 15 mg/ml. The peptide solution was then sonicated
for 5 - 10 min and filtered through a 0.2 gm nylon micro-spin filter
(Whatman Inc., Clifton, NJ) to remove any undissolved seed. Final peptide
concentrations of the DMSO stock solutions, as determined by quantitative
amino analysis, were typically 2-2.5 mM.
In vitro aggregation of Al1-40.
AP aggregation was initiated by adding an aliquot of a concentrated DMSO
stock of A31-40 to aqueous buffer (10 mM phosphate, 137 mM NaC1, 27 mM
KC1, pH 7.4, unless otherwise specified) followed by immediate vortexing to
mix thoroughly. For experiments investigating the concentration
dependence of protofibril elongation, DMSO in the aggregation buffer was
kept constant ( < 5% by volume) by adding DMSO to the sample buffer of the
less concentrated Apl-40 solutions to make sure that any effect of DMSO on
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the rate of assembly would be the same in each sample. After initial mixing
the solutions were incubated at room temperature without further agitation
except for the minimal disturbance caused by removing aliquots for AFM
analysis.
General methods for AFM analysis
Specimen preparation. AFM specimens were prepared by removing 3-5 gL
aliquots from peptide suspensions and placing them on freshly cleaved mica
(Ted Pella Inc., Redding, CA). After incubating for between 30 seconds and 2
minutes, the remaining suspension was removed by rinsing twice with 50 tL
water to remove salt and loosely bound peptide that can interfere with image
quality. Excess water was removed with a gentle stream of difluoroethane
(Dust-Off Plus, Falcon Safety Products Inc.) and the samples were stored in a
covered container to protect them from contamination until they were
imaged (within 1-2 hours).
Optimization of protofibril adsorption density. For accurate measurements of
the lengths of protofibrils adsorbed to mica, specimens with well dispersed
protofibrils are neccesary to minimize uncertatainty when determining the
beginning and end of individual protofibrils for measurements. Protofibril
distributions were controlled by diluting the samples immediately prior to
specimen preparation and by adjusting the time that the protein suspension
was incubated on the mica surface prior to rinsing. Typically, incubating AI1-
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40 aggregate suspensions at 15-25 pM for between 30 seconds and 2 minutes
produced specimens with protofibril distributions suitable for determining
length averages. The amount of dilution and the incubation time were
adjusted for each set of samples at the initial time point and were kept
constant for all subsequent analyses within that series. Whenever high
concentrations of peptide were studied, specimens for AFM were prepared
immediately after dilution to the desired concentration (typically 15-25 gtM).
Keeping dilution times as brief as possible minimized the possible effects of
dilution on protofibril lengths
Atomic force microscopy. All images were obtained under ambient
conditions with a Nanoscope IIIa Multimode scanning probe workstation
(Digital Instruments, Santa Barbara, CA) operating in TappingModeTM using
etched silicon NanoProbesTM (probe model FESP, Digital Instruments).
Scanning parameters varied with individual tips and samples, but typical
ranges were as follows: initial root mean square (RMS) amplitude, 1.6 V;
setpoint, 1.1-1.4 V; tapping frequency 70-90 kHz; scan rate 1.5-2 Hz.
Consecutive scans were monitored until distortion due to creep or shifts in
the slow scan direction were negligible before collecting scans at sizes of 1 p m
with the maximum 512 x 512 pixel resolution (occasionally 2 pM scan sizes
were used when protofibril adsorption density was too low to find 50
protofibrils in a 1 pM square region).
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Protofibril length measurements
Average protofibril length. An area containing 50-100 protofibrils was chosen
from the original image, and all protofibrils within this region were
measured by summing the lengths of short line segments (in top view mode
in the Nanoscope software) approximating the curvature of the protofibrils.
Globular aggregates measuring < 20 nm and showing no evidence of
elongation were counted in each region and included in the calculation of
average protofibril length as described below. Protofibrils which were not
entirely within scanned area were excluded from the measurements unless
they extended into an adjacent region where data was collected and could be
traced for accurate determination of their lengths. In some instances groups
of protofibrils were too intertwined for all of the individual species to be
distinguished, so only protofibrils that could clearly be distinguished were
included in the average.
Before calculating the average we subtracted 8.5 nm from each
measured protofibril length to remove the contribution of tip related
broadening artifacts from the measurements. The 8.5 nm adjustment value
was obtained experimentally by measuring the average protofibril width at
half height (12.8 ± 2.5 nm) in representative scans from these experiments
and subtracting the approximate value for protofibril diameter in the same
scans (4.3 nm, Figure 3.3). Each ~4 nm globular feature (no evidence of
elongation & widths < 20 nm) in the region was listed as a protofibril with
length = 4.3 nm. This list was divided by the number of protofibrils +
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globular features to yield the average protofibril length. Typical scans used for
these measurements were 1 gm square scans captured at highest resolution
(512 x 512 pixels), giving a pixel size is -2 nm. The estimated error of ± 5 n m
listed for protofibril average length measurements is based in part on the ± 2
pixel error of each protofibril measurement (± 1 at each protofibril end = ± 4
nm) and on the variability in repeated length average measurements from
the same sample which generally fell within a 5 nm range.
Length of longest protofibril. Using the same scans containing the region
used for average length measurements, we divided each scan into quadrants
and then found and measured the longest protofibril present in each
quadrant. We then calculated the average of these lengths and used this
value (± the standard deviation of the individual measurements included in
the average) to represent the length of the longest protofibril. The averaging
method was used instead of relying on the length of a single protofibril to
improve confidence that the value obtained is an accurate representation of
the longest protofibrils present and to provide some sense of the variability of
this measurement.
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Chapter 4
Seeding Behavior and Morphological Clues Lead to an Expanded
Model for the AP Fibril Assembly Process
AFM images of early in vitro AF amyloid fibril formation reveal the
existence of a family of elongated A3 oligomers, of heterogeneous length,
which differ from the much longer product fibrils with respect to their height
and surface morphology. These oligomers, collectively designated protofibrils,
appear well before fibrils are observed, grow over a period of weeks in the
absence of agitation and then disappear rapidly as fibrils grow. The protofibril
is approximately 3-4 nm in height and has a periodicity of ca. 20 nm, as
compared to the type 1 fibril which has a height of 7-8 nm and a periodicity of
ca. 40 nm. Two explanations for the transient appearance of the protofibril
were put forward; the protofibril could be an off-pathway "reservoir phase",
in rapid equilibrium with monomeric A3, or an on-pathway assembly
intermediate, from which fibrils are constructed. 1,2 In the latter case, the
protofibril would also be expected to be the preferred substrate for fibril
growth.
This chapter discusses AFM observations of the seeded polymerization
of Apl-40 which provide insight into the role of the protofibril in in vitro
fibril formation. Analysis of the effect of preassembly on the efficiency of
seeded fibril formation and careful examination of fibrillar structures
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indicates that the protofibril is likely to be an assembly substrate for fibrils. In
addition, decreases in filament flexibility following protofibril incorporation
into fibrils and associated increases in filament resistance to denaturation
imply that a conformational change may be a driving force in fibril
formation. These observations combined with results discussed in the
preceding chapters form the basis of a new testable model of in vitro fibril
formation which may provide insight into amyloid formation in vivo.
Protofibril elongation and fibril elongation may be distinct processes.
A31-40 and A3l-42 follow analogous pathways to the fibril, including
the early appearance of protofibrils which elongate and eventually disappear
as fibrils grow. Since aggitation accelerates fibril formation (Chapter 2), the
studies reported herein were performed with as little agitation as possible to
maximize our chances of observing the more rapid seeded fibril growth
process. In addition, the AB variant A3l-40, rather than A31-42, was used
because it forms fibrils after a longer lag phase (Chapter 1, 2), making it easier
to observe transient protofibrils and reducing the likelihood that spontaneous
nucleation would contribute to our observations.
Although AP31-42 seems to be the pathogenic species in early-onset
FAD based on accumulating genetic evidence, 3 pathological observations of
the AD brain suggest that A3l-40 also plays a critical role in AD.4 First, the
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increased deposition of Apl-40 is characteristic of late-onset AD patients
bearing the apoE4 allele which is a susceptibility factor for AD. 5  The
postmortem examination of brains of individuals with Down syndrome (DS)
also points to the importance of A31-40 in AD. The brains of DS patients
show numerous non-fibrillar A3l-42 containing diffuse plaques as early as 12
years of age.6 However, pathological evidence of neurodegeneration
(dystrophic neurites, activated microglia) did not appear until around age 30,
when mature Apl-40 containing plaques also began to appear.6 Therefore,
although AB1-42 appears to be an important initiating factor in early onset
forms of AD, the accumulation of Apl-40 may also contribute significantly to
the development of neurodegeneration in AD.
Evidence from seeding behavior
Addition of AB1-40 amyloid fibrils to a supersaturated solution of AP1-
40 reduces or eliminates the lag phase prior to aggregation (as detected by
turbidity).7-9 AFM analysis shows that the conversion of a freshly diluted
supersaturated Apl-40 solution (100 [pM) to amyloid fibrils at room
temperature was similarly accelerated (Figure 4.1) by the addition of an
aliquot from an Apl-40 solution containing a mixture of fibrillar
morphologies but no protofibrils (Figure 4.1). The total amount of Afl-40 in
the seed aliquot was ca. 1% the amount present in the supersaturated
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solution. No fibrils were observed when the same amount of fibrils was
diluted into buffer alone and used to produce specimens, so the appearance of
fibrils can be attributed to new fibril growth and not just the detection of the
seed material. In the seeded conversion, fibrils were clearly visible after 3
days; in the absence of seed, fibrils generally did not appear until at least 15
and usually > 21 days had elapsed. Protofibrils were no longer present in
specimens prepared from the seeded conversion by 14 days; in the absence of
seed, protofibrils were still present along with fibrils after 30 days.
In a separate experiment, starting with a similar solution of A31-40
(100 pM, freshly diluted), addition of an aliquot (also containing ca. 1% the
amount present in the supersaturated solution) from a solution containing
protofibrils, but no fibrils (by AFM), resulted in no observable fibril growth by
4 days following the addition of the protofibrillar seed (Figure 4.2, center). A
parallel sample seeded with the same amount of AP1-40 in the form of fibrils
contained growing fibrils by day 4 (Figure 4.2, right).
Not all fibrillar preparations of Apl-40 were equally effective as seeds
in similar experiments. This suggests that either certain fibrillar
morphologies are more effective seeds, or that the seeding and incubation
conditions used for these room temperature experiments are not optimal for
promoting fibril growth. Similar considerations may also explain why the
observation of heterogeneous seeding of Al1-40 fibril growth by Apl-42 fibrils
has been observed to be very inconsistent (data not shown).
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Figure 4.1: Images of unseeded samples and samples seeded with preformed
fibrils. TOP ROW: Three AFM images showing snapshots of an unseeded
100 p~M Al1-40 at the indicated times after dilution. SECOND ROW:
Snapshots at the same times of a identical parallel sample of Apl-40 that was
seeded immediately following dilution with a suspension containing
preformed Al1-40 fibrils but no protofibrils. BOTTOM: An image of a
specimen prepared with the seed material used (left), and a mechanistic
model (right) showing the key finding--preformed fibrils greatly accelerate the
converison of protofibrils to fibrils. All images are 2 gm square.
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Figure 4.2 The effect of adding preformed protofibrils or protofibrils to freshly
diluted A solutions. Apl-40 solutions (100 gM) were seeded with aliquots of
preformed protofibrils (center) or fibrils (right) (the amount of AD in the
aliquots represented ~1% of the amount in the supersaturated solution).
Images are 2 pm square.
The seeding behavior of the enantiomeric fibrils was also examined as
a control for the specificity of the seeding event. Aliquots of protofibrils
formed by each Apl-40 enantiomer (100 gM) were separately seeded by adding
fibril suspensions (5% of the initial AP concentration) formed by either the
same or the opposite enantiomer and compared to unseeded control
solutions. Acceleration of fibril formation was observed when all-L fibrillar
seed material was added to the freshly diluted solution of all-L A31-40 (Figure
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4.3, center). Addition of the same amount of preformed all-D fibrils had no
effect. Similarly, for supersaturated solutions of all-D Al1-40 only addition of
preformed fibrils made from all-D Al1-40 accelerated fibril formation, while
fibrils formed by all-L A01-40 had no effect (not shown). This is consistent
with previous observations of amyloid seeding specificity. 10
Figure 4.3 Seeding behavior with enantiomeric AD fibrils. Solutions of all-L
Apl-40 (100 pM, room temperature incubation) were either left unseeded
(left), seeded with all-L A1l-40 fibrils, or seeded with all-D A1l-40 fibrils (5%
seed added based on initial AB concentrations). All images were collected 10
days after initial dilution and seeding and are 5 pm square.
The observation by AFM that the transition of A31-40 to fibrils can be
accelerated by adding preformed fibrillar AB aggregates is consistent with
previous observations using turbidity of a reduced lag time or nucleation
phase for Al1-40 aggregation following addition of preformed fibrillar seed
material. Accelerated fibril growth is not observed following the addition of
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protofibrils but is only observed when the added material contains filaments
and fibrils. This suggests that the rate limiting step or nucleation event in
fibril formation is not the formation of protofibrils, but is the process that
results in the formation of the first fibril in the supersaturated solution.
Furthermore, the ability to selectively accelerate fibril formation implies that
the process responsible for fibril formation is fundamentaly different from
the process responsible for protofibril elongation.
Evidence from growth rate estimates
As described in Chapter 3, an estimate of the elongation rate for a
growing filament species can be made by finding the longest filament on a
specimen and dividing the change in length by the time elapsed since
dilution. A rough estimate of the protofibril elongation rate can be obtained
in this way by examining an Apl-40 solution (100 gM) incubated for 2.5 days
at room temperature before analysis by AFM (left image in Figure 4.4). The
maximum protofibril length observed on the specimen was 242 nm.
Assuming an initial length for that protofibril of 4 nm (approximately equal
to the protofibril diameter), then the estimated protofibril elongation rate
under these conditions was 95 nm per day. A similar estimate of the
maximum rate of fibril elongation can be made from the observation of fibril
lengths in a supersaturated solution of Apl-40 (100 pM, pre-incubated 8 days
prior to seeding) two days following the addition of fibrillar seed (1% based on
inital Apl-40 concentration). Fibrils can frequently be observed to cross an
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entire 10 gm square region of the specimen prepared from this sample (right
image in Figure 4.4). Assuming an initial fibril length of 5 gm (compare to
image of similar seed material shown in Figure 4.1) and limiting the
maximum fibril length to the 10 gm scan size provides a conservative
estimate for the rate of fibril elongation of 2500 nm per day--a value an order
of magnitude greater than the maximum protofibril elongation rate.
Figure 4.4 Images used for estimating protofibril and fibril elongation rates.
The 2 gm square image on the left shows protofibrils grown by A31-40 after
2.5 days. The 10 gm square image on the right shows fibrils grown over 2
days following seeding (with 1% preformed fibrils) a solution of AB1-40 (100
pM, preincubated for 8 days prior to seeding).
This dramatic difference in the apparent elongation rate for protofibrils
and fibrils, like the seeding behavior discussed above, supports the hypothesis
that the growth mechanisms for protofibrils and fibrils are different under
these conditions. One possible explanation is that protofibril growth may
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occur primarily by addition of monomers or small oligomers of AP to the
growing protofibril ends while fibril formation may involve direct
incorporation of pre-formed protofibrils in addition to monomer and small
oligomer incorporation.
Evidence that fibrils grow by incorporation of protofibrils
Evidence from the effects of pre-incubation on seeding efficiency
The observation of seeded protofibril-to-fibril conversion (Figure 4.1)
does not prove that protofibrils are on-pathway intermediates in fibril
formation. Protofibrils could also merely serve as an off-pathway reservoir
phase for AP. To try to distinguish between these alternatives, we sought to
investigate the relationship between protofibril formation/growth and the
time course of the seeded conversion (Figure 4.5). Our methodology does not
allow us to measure the amount of protofibrils directly (Chapter 3).
Therefore, to compare the extent of protofibril formation we instead refer to
the relative length of protofibrils, which, like the amount of protofibrillar
Apl-40,(12) increases over time (also Chapter 3).
For the off-pathway scenario, the seeded fibril formation rate should
show no dependence on the extent of pre-assembly/pre-population (no
difference between seeding at time 1 or time 2 in Figure 4.5) if the exchange
rate between protofibrillar and monomeric AP (or the species responsible for
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fibril growth) is faster than the rate of incorporation of A3 into fibrils.
Circumstantial evidence suggests, however, that the exchange rate may be
relatively slow. When Af1-40 protofibrils are isolated from low molecular
weight precursors using size exclusion chromatography and dialyzed against
buffer without AP using membranes which allow monomeric AP but not
protofibrils to pass through, fibrils can form inside the dialysis membrane
(observed by negative stain EM, Dominic Walsh and David Teplow--
unpublished observations). The ability of fibrils to form before the
protofibrils disassemble in this dialysis experiment suggests that the
protofibril to fibril transition is faster than protofibril dissolution.
For the off-pathway model, slower conversion of preincubated A3
solutions to fibrils following seeding would be expected if exchange between
the protofibrils and the assembly substrate is slow compared to association of
the assembly substrate to growing fibrils. However, if protofibrils are
assembly substrates in the pathway leading to AP fibrils, the effect of
preassembly may be reversed. In the on-pathway scenario, pre-incubation
would pre-populate a substrate for fibril growth. Therefore, pre-incubation
should accelerate the seeded transition to fibrils if growth by incorporation of
protofibrils is more productive growth by incorporation of smaller forms of
A3. However, if all of the species on the pathway (monomers, oligomers(?),
protofibrils, etc.) are equally productive substrates for fibril growth, then pre-
incubation may have little effect.
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Figure 4.5 Two possible roles for the protofibril in fibril formation.
Protofibrils increase in length and number with time in both scenarios, but
may be an off-pathway reservoir phase of AP (top), or on-pathway assembly
substrates for fibrils (bottom). It may be possible to distinguish between these
scenarios experimentally by comparing the progression toward fibrils in
samples seeded without prior incubation (at time 1) to the time course for
fibril formation in parallel samples seeded following pre-incubation (at time
2) to populate protofibrils (as discussed in text).
As shown in Figure 4.6, the seeded conversion of protofibrils to fibrils
occurred much more rapidly from an incubation containing longer
protofibrils (Figure 2, bottom panels; AB1-40 (100 RtM) was preincubated for 13
days before seeding) as compared to an incubation containing short
protofibrils but an equal total A31-40 concentration (top panels, A1l-40 (100
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jM was preincubated less than 5 minutes before seeding). In the absence of
added seed, fibrils were not observed in the incubation containing short
protofibrils after 7 days. One day after seeding the non-pre-incubated
solution, no evidence of fibril formation was seen, and only isolated fibrils
were seen among protofibrils at 4 days. By 7 days, long fibrils had become
more common, but the presence of numerous protofibrils indicated that fibril
formation was still not complete (Figure 4.6, top panels).
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Figure 4.6: The effect of pre-incubation time on seeding efficiency. Al1-40
(100 gM) was preincubated for 5 minutes (top row) or 13 days (bottom), then
preformed fibrils were added to seed the conversion to fibrils. The 5 minute
sample containing shorter protofibrils was slowly converted to fibrils by
addition of seed material (top), whereas conversion in the 13 day sample
containing longer protofibrils occured more rapidly (bottom).
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In contrast, long (> 5 jm) fibrils were commonly observed in the pre-
incubated solution one day after seeding. The amount of protofibrils on the
substrate decreased noticeably by day 4 as fibrils became more numerous.
After 7 days, protofibrils were rare and fibril formation appeared to be almost
complete (Figure 4.6, bottom panels). Comparing these observations to the
hypothetical seeding scenarios discussed above suggests that the accelerated
seeded transition to fibrils in preincubated A11-40 solutions (compared to
otherwise identical freshly diluted Apl-40 solutions) is consistent with fibril
growth by protofibril incorporation.
Given the clear effect of temprerature on protofibril growth (Chapter 3),
it is possible that temperature may also have an important effects on the
progress of seeded fibril growth as well. We are currently investigating the
effects of pre-incubation on seeding behavior at 37'C to see if similar effects
are observed at temperatures approximating those found in the body.
Morphological observations are also consistent with fibril growth by
protofibril incorporation
Fibrils have an inherent helical twist.
Images of the type 1 fibril at high magnification clearly show a left-
handed helical orientation to the periodic height increases (period = ~ 43 nm)
along the length of type 1 fibrils formed from all-L Al1-40. The top two
images of Figure 4.7 show details of a type 1 fibril formed by all-L Apl-40. The
helical nature of the periodic height increases along the length of the fibril is
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apparent in the height image on the top left. The left-handed orientation of
the helix is more clearly resolved in the image on the right generated by
plotting simultaneously acquired cantilever oscillation amplitude data which
emphasizes rapid changes in height (bright areas correspond to decreases and
dark areas to increases in cantilever oscillation amplitude during the scan).
Figure 4.7 Helicity of Apl-40 type 1 fibrils. Top: Type 1 fibrils formed by all-L
A11-40 imaged in height mode (left) and amplitude mode (right). Bottom:
Type 1 fibrils formed by all-D A1-40 imaged in height mode (left) and
amplitude mode (right). Scale bar = 50 nm.
It is possible that simple beaded objects could have a helical appearance
if the tip used to scan them was irregularly shaped, but two separate
observations rule out this possibility. First, the observed helicity is the same
regardless of orientation of the fibrils in the image (data not shown).
Furthermore, type 1 fibrils formed by all-D Apl-40 showed identical
periodicity of the height increases and were also clearly helical (Figure 4.7,
bottom), but the twist direction was always observed to be right handed
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(Figure 4.7, bottom right). Although the fibrils appear to have different
widths, the heights of adsorbed type 1 fibrils formed by each peptide are
indistinguishable, and width differences of this magnitude are consistent
with variations in broadening artifacts caused by differences in tip shape.
The observed helicity is consistent with fibril formation by lateral
association and winding of protofibrils or filaments to form the fibril.
Dependence of helical handedness on the enantiomer of AP forming the
fibril indicates that the orientation of winding is not determined randomly,
but may arise from specific filament contact orientations or from the structure
of the filaments themselves.
Observation of staggered filaments at type 1 fibril ends.
As protofibrils disappeared in seeded AB1-40 solutions, type 1 fibrils
became the predominant morphology. Images of the ends of type 1 fibrils
produced with standard silicon AFM probes were sometimes characterized by
what appeared to be staggered termination of filaments (Figure 4.8). Single
filament extensions have been observed with lengths of tens of nanometers
to a micron or more (some longer examples can be seen in Figure 4.10). These
staggered ends could result from imperfect alignment of two protofibrils or
filaments during assembly. As filament contacts are maximized during
winding, imperfectly aligned filaments would form a type 1 fibril with a
single filament extending beyond the end of the shorter protofibril/filament.
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Figure 4.8 Images of staggered filaments at the end of type 1 fibrils. LEFT: A 1
gm image generated with a standard silicon probe resolves a single filament
extending from the end of a type 1 fibril (arrow). RIGHT: A 250 nm image
generated using a carbon nanotube tip clearly resolving a short single
filament extension and the termination of the shorter filament.
Utilization of newly developed nanotube probes11 made by Stan Wong
from Professor Charles Lieber's group at Harvard, provides significantly
improved resolution of A fibrils. 12 These tips are made by attaching carbon
nanotube bundles to the tips of standard silicon AFM probes.
11,12 Imaging
with nanotube probes provides improved resolution by decreasing the radius
of curvature and increasing the aspect ratio of the tip thereby minimizing the
broadening effects caused by tip-sample interactions. 12  The improved
resolution made possible with these nanotube tips provides a much clearer
image of this feature and clearly shows the terminus of the shorter filament
as well as the short extension of the longer filament (Figure 4.8, right).
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Figure 4.9 Imperfect winding in type 1 fibrils. LEFT: A 500 nm square image
of fibrils generated using a standard silicon probe. RIGHT: Image generated
using a nanotube probe--arrow indicates imperfection (scale bar = 200 nm).
Imperfections in type 1 fibrils
Type 1 fibrils with closely associated protofibrils commonly appear at
intermediate stages of fibril formation when protofibrils are still numerous
(for example, see the 4 day image of the pre-incubated sample in figure 4.6).
The overall appearance of these features resembles what one would expect to
see if protofibrils in the process of winding to form type 1 fibrils were trapped
by adsorption to the substrate. However, since protofibrils are still relatively
abundant at these time points, one would expect a number of protofibrils to
adsorb near fibrils regardless of whether they were actually associated in
solution. Sometimes, however, features appearing to be type 1 fibrils trapped
in the process of winding can also be seen at much later time points when
isolated protofibrils are not observed (Figure 4.9, left image). Protofibrils
140
associated to fibrils in features such as this one (from a seeded Apl-40 soluion,
t = 40 days), are more likely to represent protofibrils that have been trapped in
the process of winding.
Less striking disruptions in the periodic helical substructure of type 1
fibrils can also be clearly observed using nanotube tips. The right image in
Figure 4.9 shows examples of this disruption in the middle of the type 1 fibril.
Imperfections such as this one may represent gaps in one of the strands
forming the fibril caused by failed ligation of protofibrils/filaments during the
assembly process. This failed ligation could be explained either by association
of protofibrils or filaments in an orientation such that the adjacent ends are
not close enough to be ligated, but are too close for incorporation of an
additional protofibril. Alternatively, the formation of very small overlaps
during assembly could interfere with proper ligation of filaments but produce
extensions that are too short to support association and incorporation of
further protofibrils to produce a branched structure (see discussion on branced
structures below).
Observations of partially wound type 1 fibrils and isolated filaments
At late time points in the Apl-40 fibril formation process, after
protofibrils have disappeared, junctions between type 1 fibrils and two
filaments with smaller diameters can sometimes be observed (Figure 4.10).
These structures appear to be partially wound type 1 fibrils and suggest a two
filament architecture for type 1 fibrils. The average diameter of the filaments
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was 3.6 ± 0.4 nm (within the range of protofibril diameters observed
previously), and type 1 fibrils in the same image had a diameter of 9.2 ± 0.2
nm. These filaments had regular increases in diameter along their axes with
a period of 38 ± 4.4 nm that was very similar to the periodicity of type 1 fibril
diameter increases (see section in figure 4.11). Isolated filaments with the
same diameter and periodicity were also seen (again, only after the complete
disappearance of fibrils) and may result from complete unwinding of type 1
fibrils, or from single filament extensions becoming detached from type 1
fibrils as a result of shearing forces generated during the sample preparation
process. The lengths of the filaments observed both in isolation and as part of
type 1 fibrils were often greater than 1 gm.
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Figure 4.10 Rigid filaments are seen both in isolation and as part of partially
wound Ap1-40 type 1 fibrils. Image sizes: left = 750 nm square, right = 2 g m
square.
Junctions between type 1 fibrils and two long filaments with smaller
diameters apparently represent partially wound or unwound type 1 fibrils
that exist at least transiently in solution and become trapped by adsorption to
the mica substrate. An on-pathway role for protofibrils in fibril formation
would suggest that these long filaments are the result of simple ligation of
protofibrils following lateral association and winding of protofibrils to form
type 1 fibrils. This idea is supported by the similar diameters of the protofibril
and filament and by the observation of single filaments that are an order of
magnitude longer than the longest protofibrils observed during fibril growth
in the sample. However, subtle differences in the apparent structure of these
two morphologies provide evidence that the process of filament formation
may involve more than ligation of protofibril ends in the context of a
growing fibril (see below).
Branched type 1 fibrils were observed.
Branched type 1 fibrils were commonly observed during fibril
formation while protofibrils were still abundant (examples in Figure 4.6) and
also following the apparent completion of fibril formation (Figure 4.11). At
some branch points, all of the diverging fibrils resembled type 1 fibrils (top of
left panel). At others, one of the branches was a long single filament
extension of one of the type 1 fibrils (Figure 4.11, right panel).
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Figure 4.11. Images of branched type 1 fibrils. The left image (1 gm square)
shows a fibril that is partially wound at one end and branched at the other.
The inset shows a schematic interpretation of the morphology. The right
image shows a 500 nm square image showing branching in more detail. The
inset shows a cross section along the indicated plane (arrow) that shows the
transition from 8-9 nm type 1 fibril to 3-4 nm single filament and shows the
40 nm periodicity of height increases along the length of both the filament
and the fibril.
Branched fibrils are a reasonable product in a fibril formation process
involving association and winding of protofibrils. During assembly,
improperly staggered protofibrils could associate with the growing fibril and
leave exposed single filament extensions protruding from the side of the fibril
at points of overlap. Association and incorporation of a protofibril with the
protruding filament could then produce a new fibril extending from the
existing fibril at the original overlap site. Partially wound type 1 fibrils appear
to exist at least transiently in solution (above), and could also result in
branched fibrils by a similar mechanism. Branching increases the number of
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fibril growth sites, and could lead to geometric amplification of the overall
rate of incorporation of AP into fibrils with time if repeated branching occurs.
This amplification effect would be similar to the autocatalysis that is observed
during fibril formation by sickle cell hemoglobin in vitro that has been
explained in terms of a double-nucleation model. 13 In the double nucleation
model the sides of existing fibrils promote the formation of new oligomeric
nuclei at a rate related to the surface area of the fibrils present. Since the
available surface is continuously increasing as fibril growth proceeds the rate
of side-nucleation also increases and provides a scenario which can explain
the autocatalysis of hemoglobin fibril growth. 13
Although amyloid fibrils are typically described as unbranched in the
literature, our observations of branching are not entirely unprecedented.
Light scattering data from in vitro fibril formation has been interpreted to
reflect a low degree of Al1-40 fibril branching under certain conditions.14 In
addition, branched Al1-40 fibrils formed in vitro have also been visualized
previously by EM of rotary-shadowed specimens 15 and AFM imaging under
isopropanol. 16
A conformational change may occur during fibril formation.
Indications from denaturation studies.
Evidence for a conformational change during fibril and filament
formation can be seen in experiments which investigate the relative
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resistance of protofibrils vs. filaments and fibrils to disassembly following
exposure to guanidine hydrochloride (GuHC1). In the first experiment,
aliquots containing 50 pgM Al1-40 (either containing protofibrils and other
small oligomers present prior to fibril formation, or containing fibril and
filament morphologies but no protofibrils) were diluted to a final Apl-40
concentration of 25 gpM in buffer containing no GuHCl, 1 M GuHC1, or 3 M
GuHCl. Following incubation for 24 hours at room temperature, the samples
were used to prepare specimens on mica for analysis by AFM.
No GuHCI 1M GuHCI 3M GuHCI
Figure 4.12 Comparison of the resistance of protofibrils (top) and filaments &
fibrils (bottom) to denaturation by GuHC1. All images are 2 pm square.
146
t = 46 days
No GuHCI
3 M GuHCI
Figure 4.13 GuHCl does not decrease adsorption of protofibrils to mica at
short incubation times. Aliquots of the same A31-40 (50 pM) solution
containing protofibrils and occasional fibrils were diluted to 25 gM with water
(top) or 6M GuHCl (bottom) and used to prepare samples for imaging after the
indicated incubation times at room temperature. Images are 1 gm square.
The images in Figure 4.12 show that after 24 hours of incubation
protofibrils are abundant in the dilution without GuHC1, are seen with
reduced frequency on the mica surface prepared from the suspension in 1 M
GuHCl, and are entirely absent on the substrate prepared from the suspension
in 3 M GuHCl (Figure 4.12, TOP). In contrast, fibrils can be observed for all
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I
t = 1 min
concentrations of GuHC1 examined (Figure 4.12, BOTTOM). It is also clear
that single filaments are more stable than protofibrils since several single
filament extensions of type 1 fibrils can be seen in the 3 M GuHCl treated fibril
sample (Figure 4.12, bottom right).
The disappearance of protofibrils in the images prepared from GuHCl
containing samples suggested that protofibrils have been disaggregated in
these suspensions. However, since the effects of GuHCl on the adsorption
process were not known, it was also possible that GuHC1 caused the
disappearance of protofibrils by selectively interfering with their adsorption to
mica. To control for this possibility, aliquots from a 50 gM A1l-40 suspension
which produced specimens on mica with mostly protofibrils and only widely
scattered fibrils were diluted to 25 jiM with water or 6 M GuHCl to produce
suspensions without GuHCl or with 3 M GuHC1. Specimens prepared from
these suspensions 1 minute after dilution clearly showed the presence of
numerous protofibrils in the sample containing 3 M GuHC1 as well as the
sample diluted with water (Figure 4.13, left).
Imaging specimens prepared from the same suspensions after
incubation at room temperature for 46 days confirms the previous
observation that protofibrils are stable upon dilution to 25 [M, but are
destroyed by prolonged exposure to 3 M GuHCl (Figure 4.13, right). In
addition, the persistence of fibrils, but not protofibrils, after 46 days in the 3 M
GuHCl sample provides another demonstration (this time from a single
sample) that protofibrils are more sensitive to denaturation by GuHCl
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compared to fibrils and filaments. If filaments are the product of protofibril
ligation in the context of type 1 fibrils, the increased resistance of filaments to
denaturation compared to protofibrils could be explained if a stabilizing
conformational change occurs during fibril assembly.
Indications from differences between protofibrils and filaments.
Simple end-to-end ligation of winding protofibrils should produce
filaments with morphological features like protofibrils that differ only by
increases in length. However the filament clearly differs from the protofibril
in several ways. The small height increases along the length of the filaments
shown in Figure 4.11 have a periodicity of ~40 nm. This distance is
approximately twice the distance observed for periodic height increases along
the protofibril (which have a -20 nm period). Furthermore, when filaments
are compared to fibrils they appear to be more rigid (they show much less
curvature when adsorbed to the surface than protofibrils do). Finally,
although the average diameter of filaments is similar to the protofibril (as
discussed above), comparison with type 1 fibrils in the same image shows that
filament diameters are about 40% of type 1 fibril diameters. This is less than
the height of protofibrils relative to type 1 fibrils which is usually ~48%
(Chapter 2). Each of these changes could be an indication that a
conformational change occurs as protofibrils are incorporated into
protofibrils.
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A Model For A Fibril Formation
A schematic summary of the temporal evolution of the Apl-40-
derived species imaged herein is shown in Figure 4.14. The observed species
fall into three classes, based on the their dimensions and surface topography
as determined by AFM. First to appear are the flexible protofibrils, which
have an axial periodicity of ca. 20 nm, and are 3-4 nm in height. Protofibrils
grow slowly (to ca. 200 nm) until type 1 fibrils are observed, then are rapidly
consumed. The protofibrils are in equilibrium with monomeric AP; slow
dissolution of protofibrils occurs at high dilution (data not shown). The next
species to appear are type 1 fibrils; usually well over 1 gm long, with a helical
structure (axial periodicity of ca. 40 nm), and a height that is approximately
2.5-fold that of the protofibril. After the protofibrillar population has been
consumed, filaments appear that are rigid and long like type 1 fibrils, have
axial periodicity resembling the type 1 fibril, but have a height that is similar
to that of the the protofibril. The dimensions of these classes are consistent
with a two-filament wound morphology for the type 1 fibril; this morphology
is well-precedented (discussed in Chapter 2). The morphological differences
between the rigid filaments and the flexible protofibrils may reflect a critical
conformational change (red to green in Figure 4.13). A conformational
change is also supported by the increased resistance of filaments and fibrils to
denaturation by guanidine compared to protofibrils.
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Figure 4.14: Temporal evolution of Apl-40-derived species. Top row: At the
earliest time points the only observed Apl-40 aggregates are short protofibrils.
Second row: Subsequently, longer protofibrils become increasingly common.
Third row: After 3-4 weeks, or 1-7 days following the addition of preformed
fibrils, both protofibrils and long type 1 fibrils are seen. Branching of fibrils is
frequently observed at this stage (see days 4 and 7 in Figure 2). Fourth row: In
the late stages, protofibrils are no longer observed. In addition to type 1 fibrils
and branched type 1 fibrils, isolated rigid filaments and junctions are
observed.
The intermediacy of the AP protofibril necessitates a modification of
the nucleation-dependent polymerization model for amyloid formation. Our
current hypothesis is based on four observations reported herein, the
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transient population of the protofibril, the promoting effect of preincubation
on the seeded transition to fibrils, the wound morphology of the fibril, and
the fact that the filament morphology differs from protofibrils suggesting that
a conformational change is coupled to protofibril incorporation into fibrils. A
shematic version of this model is shown in Figure 4.15 and discussed below.
In the earliest stages of fibril formation, monomeric (or dimeric) 2 AP
rapidly oligomerizes to form short protofibrils. The average length of the
observed protofibrils (and the total amount)2 increases with time. Nucleus
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Figure 4.15 A working hypothesis to explain seeded amyloid fibril growth.
Oligomeric AP species that have been directly observed by AFM are shown in
boxes. Inferred species (not boxed) and hypothetical pathways to explain their
interconversion (dashed arrows with question marks) are included.
formation may involve annealing, winding, and an irreversible
conformational change (red to green) to produce a type 1 fibril. The
conformational change provides an explanation for the apparent
cooperativity of fibril formation and could lead to a preorganized single-
filament seed template that is an optimal binding site for addition of a
subsequent protofibril. Addition of seed containing a mixture of fibrillar
species (Figure 4.15, shown in brackets) bypasses nucleation. An exposed rigid
filament could seed growth by catalyzing a conformational change in an
added protofibril, analogous to the case in flagellar assembly.17 Addition of a
protofibril to an exposed filament could lead to unbranched elongation of a
type 1 fibril (top, bottom), or to branched morphology (middle). Fibril
elongation may also occur by addition of A3 monomer/small AP oligomer
onto filament ends.2,18,19  Detailed kinetic studies, utilizing multiple
methods to characterize and quantify all intermediates, 2 ,9,2 0 are required to
test this model.
Information about unseeded A3 fibril growth can also be inferred from
observations of seeded fibril formation. Since fibrils, but not protofibrils, are
competent seeds, the nucleation-dependent step may be the protofibril-to-type
1 fibril transition, consistent with the sudden appearance of long type 1 fibrils
as the earliest fibril morphology in both seeded and unseeded AP solutions.
The formation of the fibril nucleus could result from association and winding
of two flexible protofibrils (unboxed aligned protofibrils in Figure 4.15) in
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combination with a conformational change (red-to-green in Figure 4.15).
Protofibril association to form a nucleus should depend on the area of the
interacting surface and the frequency of collisions, and therefore, on the
length and amount of protofibrils. Alternatively annealing and winding
could be intramolecular; for example, via looping and supercoiling of a long
protofibril.
The in vitro intermediacy of protofibrils suggests that they also exist in
vivo. To demonstrate unequivocally the importance of the protofibrils in the
in vivo pathogenic process, protofibrils must be identified in, or extracted
from, AD brain tissue. Protofibrils have not been observed so far in AD brain
tissue sections nor have they been purified from AD brain. This is not
surprising since AD brain tissue is likely to represent the end-stage in the in
vivo amyloid formation process when intermediates would be least likely to
be found. Furthermore, even if protofibrils are present detection would be
hampered by the problems associated observing such small, flexible structures
in thin tissue sections, and by their potential instability to amyloid extraction
procedures. Protofibrils are most likely to be found in the brains of
individuals predisposed to develop AD such as young Down syndrome6 and
head trauma patients. 21 In both of these groups, significant deposition of AB,
in a non-fibrillar form called diffuse amyloid, precedes symptoms.6,21 These
diffuse amyloid deposits are the logical place to begin to search for protofibrils
in vivo.
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Experimental Section
Protein substrate. Synthetic A1l-40 was purchased from Quality Controlled
Biochemicals Inc. (Hopkinton, MA). All-D Apl-40 was kindly provided by
Mike Vitek (Duke University)
Preparation of seed-free A01-40 stock solutions. Stock solutions of AP1-40 in
DMSO were prepared at a concentration of approximately 12 mg/ml. The
peptide solution was then sonicated for 5 - 10 min and filtered through a 0.2
gm nylon micro-spin filter (Whatman Inc., Clifton, NJ) to remove any
undissolved seed. Final peptide concentrations of the DMSO stock solutions,
as determined by quantitative amino analysis, were typically 2-2.5 mM.
In vitro aggregation of A01-40. AP aggregation was initiated by adding an
aliquot of a concentrated DMSO stock of Apl-40 to aqueous buffer (10 mM
phosphate, 137 mM NaC1, 27 mM KC1, pH 7.4) followed by immediate
vortexing to mix thoroughly. After initial mixing the solutions were
incubated at room temperature without further agitation except for gentle
tapping to ensure homogeneous aliquots for AFM.
Seeding experiments. 100 ptM solutions of Apl-40, containing long
protofibrils ( after > 1 week preincubation) were divided. One portion was left
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unaltered and the other portion was seeded by adding pre-formed seed fibrils
and filaments (approximately 1% of a molar equivalent based on initial total
Apl-40 concentration), but no protofibrils (morphology confirmed by AFM
just prior use). At the same time, a 100 pM A11-40 solution that was not
preincubated was also seeded with the same amount of the identical seed
stock. The seed stock was diluted into buffer containing no A13-40 at the
same ratio present in seeded samples and imaged to determine the
contribution of seed fibrils to the observed images; no fibrils were detected,
indicating that the observed fibrils in the seeded growth incubations are
attributable to new growth, rather than the seed aliquot.
GuHCI denaturation experiments. Aliquots (3 jiL) of Aj1-40 (50 jiM) either
containing protofibrils and other small oligomers present prior to fibril
formation, or containing fibril and filament morphologies but no protofibrils
were diluted to a final Apl-40 concentration of 25 gM in buffer containing no
GuHC1, 1 M GuHC1, or 3 M GuHC1. Following incubation for 24 hours at
room temperature, specimens were prepared on mica an analyzed by AFM.
Atomic force microscopy. Samples were mixed by gentle tapping to evenly
suspend any aggregates, and 3-5 gl aliquots were placed on freshly cleaved
mica (Ted Pella, Redding, CA). After 30 sec, the mica was gently rinsed twice
with 50 tl of 0.2 jim-filtered water to remove salt and loosely bound peptide.
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Excess water was removed with a gentle stream of filtered compressed
tetrafluoroethane, and the samples were imaged immediately. All images
were obtained under ambient conditions with a Nanoscope IIIa Multimode
scanning probe workstation (Digital Instruments, Santa Barbara, CA)
operating in TappingMode TM  using etched silicon NanoProbes
TM (Probe
Model TESP, Digital Instruments). Scanning parameters varied with
individual tips and samples, but typical ranges were as follows: initial RMS
amplitude, 1.2 V; setpoint, 0.9-1.1V; tapping frequency, 250-350 kHz; scan rate,
0.8-1.75 Hz. Carbon nanotube probes were made by Stanislaus Wong in
Charles Lieber's lab (Harvard University) using published procedures. 12
Analysis of morphology dimensions was performed as described previously
in Chapter 2.
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